<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions to improve adherence to lipid‐lowering medication - van Driel, ML - 2016 | Cochrane Library</title> <meta content="Interventions to improve adherence to lipid‐lowering medication - van Driel, ML - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004371.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions to improve adherence to lipid‐lowering medication - van Driel, ML - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004371.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004371.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Interventions to improve adherence to lipid‐lowering medication" name="citation_title"/> <meta content="Mieke L van Driel" name="citation_author"/> <meta content="m.vandriel@uq.edu.au" name="citation_author_email"/> <meta content="Michael D Morledge" name="citation_author"/> <meta content="School of Medicine, The University of Queensland" name="citation_author_institution"/> <meta content="Robin Ulep" name="citation_author"/> <meta content="School of Medicine, The University of Queensland" name="citation_author_institution"/> <meta content="Johnathon P Shaffer" name="citation_author"/> <meta content="School of Medicine, The University of Queensland" name="citation_author_institution"/> <meta content="Philippa Davies" name="citation_author"/> <meta content="University of Bristol" name="citation_author_institution"/> <meta content="Richard Deichmann" name="citation_author"/> <meta content="Ochsner Health System" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD004371.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/12/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004371.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004371.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004371.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cardiovascular Diseases [prevention &amp; control]; Cholesterol [blood]; Cholesterol, LDL [blood]; Hypolipidemic Agents [*therapeutic use]; *Medication Adherence [statistics &amp; numerical data]; Randomized Controlled Trials as Topic; Reminder Systems" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004371.pub4&amp;doi=10.1002/14651858.CD004371.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="sogqpCtr";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004371\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004371\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004371.pub4",title:"Interventions to improve adherence to lipid\\u2010lowering medication",firstPublishedDate:"Dec 21, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004371.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004371.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004371.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004371.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004371.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004371.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004371.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004371.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004371.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004371.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5274 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004371.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-sec-0075"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-sec-0069"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/appendices#CD004371-sec-0080"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/table_n/CD004371StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/table_n/CD004371StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions to improve adherence to lipid‐lowering medication</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/information#CD004371-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Mieke L van Driel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/information#CD004371-cr-0005">Michael D Morledge</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/information#CD004371-cr-0006">Robin Ulep</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/information#CD004371-cr-0007">Johnathon P Shaffer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/information#CD004371-cr-0008">Philippa Davies</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004371.pub4/information#CD004371-cr-0009">Richard Deichmann</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/information/en#CD004371-sec-0102">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 December 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004371.pub4">https://doi.org/10.1002/14651858.CD004371.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004371-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004371-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004371-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004371-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004371-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004371-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004371-abs-0001" lang="en"> <section id="CD004371-sec-0001"> <h3 class="title" id="CD004371-sec-0001">Background</h3> <p>Lipid‐lowering drugs are widely underused, despite strong evidence indicating they improve cardiovascular end points. Poor patient adherence to a medication regimen can affect the success of lipid‐lowering treatment. </p> </section> <section id="CD004371-sec-0002"> <h3 class="title" id="CD004371-sec-0002">Objectives</h3> <p>To assess the effects of interventions aimed at improving adherence to lipid‐lowering drugs, focusing on measures of adherence and clinical outcomes. </p> </section> <section id="CD004371-sec-0003"> <h3 class="title" id="CD004371-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO and CINAHL up to 3 February 2016, and clinical trials registers (ANZCTR and ClinicalTrials.gov) up to 27 July 2016. We applied no language restrictions. </p> </section> <section id="CD004371-sec-0004"> <h3 class="title" id="CD004371-sec-0004">Selection criteria</h3> <p>We evaluated randomised controlled trials of adherence‐enhancing interventions for lipid‐lowering medication in adults in an ambulatory setting with a variety of measurable outcomes, such as adherence to treatment and changes to serum lipid levels. Two teams of review authors independently selected the studies. </p> </section> <section id="CD004371-sec-0005"> <h3 class="title" id="CD004371-sec-0005">Data collection and analysis</h3> <p>Three review authors extracted and assessed data, following criteria outlined by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. We assessed the quality of the evidence using GRADEPro. </p> </section> <section id="CD004371-sec-0006"> <h3 class="title" id="CD004371-sec-0006">Main results</h3> <p>For this updated review, we added 24 new studies meeting the eligibility criteria to the 11 studies from prior updates. We have therefore included 35 studies, randomising 925,171 participants. Seven studies including 11,204 individuals compared adherence rates of those in an intensification of a patient care intervention (e.g. electronic reminders, pharmacist‐led interventions, healthcare professional education of patients) versus usual care over the short term (six months or less), and were pooled in a meta‐analysis. Participants in the intervention group had better adherence than those receiving usual care (odds ratio (OR) 1.93, 95% confidence interval (CI) 1.29 to 2.88; 7 studies; 11,204 participants; moderate‐quality evidence). A separate analysis also showed improvements in long‐term adherence rates (more than six months) using intensification of care (OR 2.87, 95% CI 1.91 to 4.29; 3 studies; 663 participants; high‐quality evidence). Analyses of the effect on total cholesterol and LDL‐cholesterol levels also showed a positive effect of intensified interventions over both short‐ and long‐term follow‐up. Over the short term, total cholesterol decreased by a mean of 17.15 mg/dL (95% CI 1.17 to 33.14; 4 studies; 430 participants; low‐quality evidence) and LDL‐cholesterol decreased by a mean of 19.51 mg/dL (95% CI 8.51 to 30.51; 3 studies; 333 participants; moderate‐quality evidence). Over the long term (more than six months) total cholesterol decreased by a mean of 17.57 mg/dL (95% CI 14.95 to 20.19; 2 studies; 127 participants; high‐quality evidence). Included studies did not report usable data for health outcome indications, adverse effects or costs/resource use, so we could not pool these outcomes. We assessed each included study for bias using methods described in the Cochrane Handbook for Systematic Reviews of Interventions. In general, the risk of bias assessment revealed a low risk of selection bias, attrition bias, and reporting bias. There was unclear risk of bias relating to blinding for most studies. </p> </section> <section id="CD004371-sec-0007"> <h3 class="title" id="CD004371-sec-0007">Authors' conclusions</h3> <p>The evidence in our review demonstrates that intensification of patient care interventions improves short‐ and long‐term medication adherence, as well as total cholesterol and LDL‐cholesterol levels. Healthcare systems which can implement team‐based intensification of patient care interventions may be successful in improving patient adherence rates to lipid‐lowering medicines. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004371-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004371-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004371-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004371-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004371-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD004371-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004371-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD004371-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004371-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004371-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004371-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004371-abs-0002" lang="en"> <h3>Interventions to improve people's drug‐taking behaviour with lipid‐lowering drugs</h3> <p><b>Review question</b> </p> <p>Which interventions help improve people's ability to take lipid‐lowering medications more regularly? </p> <p><b>Background</b> </p> <p>Lipid‐lowering therapy has been shown to decrease the risk of both heart attacks and strokes. However, taking these medications as prescribed has not been as high as one would wish. In the past, several methods have been tried to improve the rate at which people take these lipid‐lowering treatments. Previous Cochrane Reviews have not shown a clear benefit of any particular method. We have updated our review to see if any new methods in this digital age have been tested as ways of improving these rates. </p> <p><b>Search</b> </p> <p>Our search included the 11 studies identified from previous versions in 2004 and 2010. We conducted an updated search of the same electronic databases on 3 February 2016, and we searched clinical trials registers up to 27 July 2016. </p> <p><b>Study characteristics</b> </p> <p>The people included in the studies were adults over 18 years of age in outpatient settings, for whom lipid‐lowering therapy was recommended. We now include 35 studies covering 925,171 participants in this review. </p> <p><b>Key results</b> </p> <p>Of the 35 included studies, 16 compared interventions categorised as 'intensified patient care' versus usual care. These interventions included electronic reminders, pharmacist‐led interventions, and healthcare professional education to help people better remember to take their medications. These types of interventions when compared to standard care demonstrated significantly better adherence rates both over the short term (up to and including six months) as well as the long term (longer than six months). Additionally, cholesterol levels were better over both long‐ and short‐term periods in those offered the intervention, compared to those receiving usual care. </p> <p><b>Quality of the evidence</b> </p> <p>We considered only randomised controlled trials for this review. Given the nature of the interventions, it was not possible to keep participants unaware of which group they were in. However, analysis of other forms of bias indicated that generally the studies were at low risk of bias. We assessed the evidence for the outcomes using the GRADE system, and rated it as high quality for long‐term adherence (more than six months) and for reduction in total cholesterol, and moderate quality for short‐term medication adherence (up to six months) and for LDL‐cholesterol levels. For the outcome total cholesterol levels at less than six months follow‐up, we downgraded the evidence to low quality. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004371-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004371-sec-0075"></div> <h3 class="title" id="CD004371-sec-0076">Implications for practice</h3> <section id="CD004371-sec-0076"> <p>High‐quality evidence shows that intensification of patient care interventions improves long‐term medication adherence and total cholesterol. Moderate‐quality evidence shows that intensification of patient care interventions improves short‐term medication adherence and LDL‐cholesterol. The evidence for total cholesterol reduction in the short term is of low quality. Given the importance of statin therapy in both primary and secondary prevention, strategies to improve adherence rates should have significant benefit in those people for whom statin therapy is recommended. The interventions which were identified as successful in the intensification of patient care interventions typically involved strategies beyond what a single clinician could provide. Instead, healthcare delivery systems might be better equipped to deliver the types of interventions which have been shown to best improve adherence rates. Health system‐related interventions which showed benefit involved strategies such as pharmacist‐led interventions, multidisciplinary educational or counselling sessions, and automated reminders of various types. A combination of all of these types of interventions, along with an added focus on teamwork with the primary physician, also proved to be effective (<a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>). In these studies, effectiveness was generally demonstrated by improvements in both adherence rates and in lipid levels. The effect appeared durable and was significant over both short‐term and long‐term time periods. Healthcare systems which are able to involve teams of healthcare professionals in the implementation of such interventions may well be successful in decreasing the burden of cardiovascular disease in the populations whom they serve through improved adherence to statin medications. </p> <p>The results of our meta‐analysis must, however, be seen in the context of the healthcare system in which they were trialled. For instance, the pharmacy‐led interventions are applicable in systems with a strong and well‐structured medication delivery system through pharmacies, but will not be feasible in, for instance, low‐income countries where drug dispensing is much less controlled or integrated into the healthcare system. Cultural and social context will also play a role and the impact of automated reminders delivered as text messages, for instance, will be less effective if patients' beliefs regarding their medicines have not been addressed. </p> <p>it is important to acknowledge the wide diversity of control interventions that we have grouped as 'usual care', which is different in each setting. For instance, pharmacy usual care can include patient education in some settings but none at all in others. Likewise, usual care in the context of physician‐delivered interventions can also vary extensively. The results of our comparisons therefore need to be interpreted with caution. </p> </section> <h3 class="title" id="CD004371-sec-0077">Implications for research</h3> <section id="CD004371-sec-0077"> <p>Exploration of additional factors which influence adherence to drug therapy may help in identifying other targets for interventions. These additional factors include knowledge, health beliefs, risk perception, memory, side effects of medication, costs of medication and inconvenience (<a href="./references#CD004371-bbs2-0117" title="EbrahimS . Detection, adherence and control of hypertension for the prevention of stroke: a systematic review. Health Technology Assessment1998;2(11):1-78. [www.hta.ac.uk/project.asp?PjtId=881]">Ebrahim 1998</a>). The phenomenon of adherence is complex and it would seem reasonable for interventions to address this complexity with a more patient‐centred approach. People's beliefs and preferences need to be acknowledged and incorporated into adherence‐enhancing interventions (<a href="./references#CD004371-bbs2-0126" title="MarinkerM . From Compliance to Concordance: Towards Shared Goals in Medicine taking. London: Royal Pharmaceutical Society of Great Britain, 1997.">Marinker 1997</a>). A combination of strategies including information, reminding, adherence reinforcement and emphasis on the person's perspective might lead to more effective strategies. In terms of the lipid‐lowering drug class, the main focus should be on statins, as they have been shown to be the most potent lipid‐lowering drugs (<a href="./references#CD004371-bbs2-0105" title="StoneNJ , RobinsonJG , LichtensteinAH , Bairey MerzCN , BlumCB , et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsA Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014;129(25 Suppl 2):s1-45.">ACC/AHA Guidelines 2013</a>; <a href="./references#CD004371-bbs2-0109" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet2005;366(9493):1267-78.">Baigent 2005</a>). Other important aspects for future studies include valid methods for measuring adherence and assessing the effects on serum lipid levels. Long‐term follow‐up, of 12 months and more, will reveal a more realistic picture of adherence to life‐long treatment and allow for the evaluation of morbidity and costs. Finally, studies evaluating these types of interventions on other outcomes such as morbidity, mortality, quality of life and cost effectiveness would be very useful. Data relating to which interventions were the most cost‐effective can provide guidance to healthcare systems. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004371-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004371-sec-0008"></div> <div class="table" id="CD004371-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table for the comparison of 'intensified patient care' vs 'usual care'</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intensified patient care vs usual care</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> People receiving lipid‐lowering medications<br/><b>Setting:</b> Ambulatory <br/><b>Intervention:</b> Intensified patient care<br/><b>Comparison:</b> Usual care </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with usual care</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Intensified patient care</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Medication adherence at ≤ 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.93<br/>(1.29 to 2.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,204<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>456 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>618 per 1,000<br/>(519 to 707) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Medication adherence at &gt; 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.87<br/>(1.91 to 4.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>663<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>705 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>873 per 1,000<br/>(820 to 911) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in LDL‐C at ≤ 6 months (mg/dL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in LDL‐C at ≤ 6 months (mg/dL) was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in LDL‐C at ≤ 6 months (mg/dL) in the intervention group was 19.51 greater (8.51 greater to 30.51 greater) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in total serum cholesterol at ≤ 6 months (mg/dL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in total serum cholesterol at ≤ 6 mos (mg/dL) was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in total serum cholesterol at ≤ 6 months (mg/dL) in the intervention group was 17.15 greater (1.17 greater to 33.14 greater) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>430<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in total serum cholesterol at &gt; 6 mos (mg/dL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in total serum cholesterol at &gt; 6 months (mg/dL) was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in total serum cholesterol at &gt; 6 months (mg/dL) in the intervention group was 17.57 greater (14.95 greater to 20.19 greater) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to heterogeneity<br/><sup>2</sup>Downgraded due to wide confidence interval </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004371-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004371-sec-0009"></div> <p>Despite compelling evidence about the effectiveness of lipid‐lowering drugs and the introduction of clear guidelines, lipid‐lowering therapy is still underused (<a href="./references#CD004371-bbs2-0135" title="RosensonR , KentST , BrownTM , FarkouhME , LevitanEB , YunH , et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. Journal of the American College of Cardiology2015;65(3):270-7.">Rosenson 2015</a>). Recent recommendations by the American College of Cardiology/American Heart Association are expected to significantly increase the number of individuals for whom statin therapy is indicated (<a href="./references#CD004371-bbs2-0105" title="StoneNJ , RobinsonJG , LichtensteinAH , Bairey MerzCN , BlumCB , et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsA Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014;129(25 Suppl 2):s1-45.">ACC/AHA Guidelines 2013</a>). Lack of adherence and high rates of discontinuation have been shown to be important factors in failing treatment when looking both at high cholesterol levels and at morbidity in terms of recurrent myocardial infarction (<a href="./references#CD004371-bbs2-0111" title="BlackburnDF , DobsonRT , BlackburnJL , WilsonTW . Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy2005;25(8):1035-43.">Blackburn 2005</a>; <a href="./references#CD004371-bbs2-0113" title="ChengCW , Woo K-S, ChanJC , TomlinsonB , YouJH . Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. British Journal of Clinical Pharmacology2004;58(5):528-35.">Cheng 2004</a>; <a href="./references#CD004371-bbs2-0145" title="WeiL , WangJ , ThompsonP , WongS , StruthersAD , MacDonaldTM . Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart (British Cardiac Society)2002;88(3):229-33.">Wei 2002</a>). </p> <section id="CD004371-sec-0010"> <h3 class="title" id="CD004371-sec-0010">Description of the condition</h3> <p>High cholesterol is one of the top 10 risk factors that account for more than one‐third of all deaths worldwide (<a href="./references#CD004371-bbs2-0146" title="World Health Organization. The World Health Report 2002 - Reducing risks, promoting healthy life. Available at www.who.int/whr/2002/en/whr02_en.pdf?ua=1 2002 (accessed 18th December 2016).">WHO Report 2002</a>). It is an important risk factor for cardiovascular disease (CVD), estimated to cause 18% of CVD and 56% of ischaemic heart disease (<a href="./references#CD004371-bbs2-0146" title="World Health Organization. The World Health Report 2002 - Reducing risks, promoting healthy life. Available at www.who.int/whr/2002/en/whr02_en.pdf?ua=1 2002 (accessed 18th December 2016).">WHO Report 2002</a>). There is compelling evidence for the effectiveness of lipid‐lowering drugs in reducing both lipid levels and the risk of heart attacks and strokes (<a href="./references#CD004371-bbs2-0109" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet2005;366(9493):1267-78.">Baigent 2005</a>). Elevated serum concentrations of total cholesterol (TC), low‐density lipoprotein (LDL) and total triglycerides (TRG) are associated with increased risk of coronary heart disease (CHD), whereas high‐density lipoproteins (HDL) or a low TC to HDL ratio appear to be protective. Lipid‐lowering medications (hypolipidaemics) for the treatment of hyperlipidaemia include statins, fibrates and anion‐exchange resins. Statins, in particular, have been shown in large randomised controlled trials to be effective in preventing CHD events and in reducing overall mortality (<a href="./references#CD004371-bbs2-0104" title="Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383-9.">4S 1994</a>; <a href="./references#CD004371-bbs2-0107" title="AthyrosVG , PapageorgiouAA , MercourisBR , AthyrouVV , SymeonidisAN , BasayannisEO , et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Current Medical Research and Opinion2002;18(4):220-8.">Athyros 2002a</a>; <a href="./references#CD004371-bbs2-0116" title="DownsJR , ClearfieldM , WeisS , WhitneyE , ShapiroDR , BeerePA , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279(20):1615-22.">Downs 1998</a>; <a href="./references#CD004371-bbs2-0124" title="Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. New England Journal of Medicine1998;339(19):1349-57.">LIPID 1998</a>; <a href="./references#CD004371-bbs2-0127" title="Heart Protection Study Collaborative Group. MRC/BHF Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360(9326):7-22.">MRC/BHF 2002</a>; <a href="./references#CD004371-bbs2-0138" title="SacksFM , PfefferMA , MoyeLA , RouleauJL , RutherfordJD , ColeTG , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine1996;335(14):1001-9.">Sacks 1996</a>; <a href="./references#CD004371-bbs2-0140" title="ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine1995;333(20):1301-07.">Shepherd 1995</a>). Fibrates and anion‐exchange resins achieved reductions in CHD events, but showed a non‐significant increase in non‐coronary mortality (<a href="./references#CD004371-bbs2-0116" title="DownsJR , ClearfieldM , WeisS , WhitneyE , ShapiroDR , BeerePA , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279(20):1615-22.">Downs 1998</a>). Statins are therefore recommended as first‐line therapy, whereas fibrates and anion‐exchange resins can be considered as second‐line therapy and also in combination with statins (<a href="./references#CD004371-bbs2-0141" title="Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease. A national clinical guideline.. Available at www.sign.ac.uk/pdf/sign97.pdf 2007 (accessed 11th January 2009).">SIGN 2007</a>). </p> <p>Recommendations about drug treatments vary from country to country. In the UK, treatment with statins for secondary prevention is indicated in people with clinical evidence of CVD to reduce further ischaemic events. For primary prevention of CVD, lipid‐lowering medication is recommended in asymptomatic adults who have a 20% or greater risk of developing CVD in the next 10 years (<a href="./references#CD004371-bbs2-0130" title="National Institute for Health and Care Excellence (NICE). Cardiovascular Disease: risk assessment and reduction, including lipid modification. www.nice.org.uk/guidance/cg181 (accessed 18th December 2016).">NICE 2014</a>; <a href="./references#CD004371-bbs2-0141" title="Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease. A national clinical guideline.. Available at www.sign.ac.uk/pdf/sign97.pdf 2007 (accessed 11th January 2009).">SIGN 2007</a>). A combination of statins, blood pressure‐lowering drugs and low‐dose aspirin is recommended by the World Health Report (<a href="./references#CD004371-bbs2-0146" title="World Health Organization. The World Health Report 2002 - Reducing risks, promoting healthy life. Available at www.who.int/whr/2002/en/whr02_en.pdf?ua=1 2002 (accessed 18th December 2016).">WHO Report 2002</a>) for secondary prevention of CVD, as this could cut death and disability rates from CVD by more than 50%. A meta‐analysis confirmed an approximately linear relationship between the absolute reduction in LDL‐cholesterol and the proportional reductions in the incidence of coronary and major vascular events (<a href="./references#CD004371-bbs2-0109" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet2005;366(9493):1267-78.">Baigent 2005</a>). Statin therapy resulted in a 19% proportional reduction in CHD deaths per mmol/L LDL‐cholesterol reduction. It can safely reduce the five‐year incidence of cardiovascular events largely irrespective of the initial lipid profile, relating the absolute benefit mainly to an individual's absolute risk of such events and the absolute reduction in LDL‐cholesterol achieved (<a href="./references#CD004371-bbs2-0109" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet2005;366(9493):1267-78.">Baigent 2005</a>). In England, 7000 myocardial infarctions and 2500 strokes could be avoided each year if individuals at high risk, who are not taking medication, received lipid‐lowering treatment (<a href="./references#CD004371-bbs2-0133" title="PrimatestaP , PoulterNR . Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ2000;321(7272):1322-5.">Primatesta 2000</a>). These figures show the impact of lipid‐lowering drugs on public health and thus the importance of the acceptance of and adherence to medication by the public. </p> </section> <section id="CD004371-sec-0011"> <h3 class="title" id="CD004371-sec-0011">Description of the intervention</h3> <p>Adherence is defined as the extent to which people take medication as prescribed. Since the landmark publication by <a href="./references#CD004371-bbs2-0137" title="SackettDL , HaynesRB . Compliance with Therapeutic Regimens. Baltimore: John Hopkins University Press, 1976.">Sackett 1976</a>, it has been the focus of research over the last three decades (<a href="./references#CD004371-bbs2-0143" title="VermeireE , HearnshawH , Van RoyenP , DenekensJ . Patient adherence to treatment: three decades of research. A comprehensive review. Journal of Clinical Pharmacy and Therapeutics2001;26(5):331-42.">Vermeire 2001</a>). Adherence can either be intentional or non‐intentional, and is determined by a variety of factors such as lack of knowledge, denial, adverse effects, poor memory and adverse attitudes to treatment. Reliable indicators of adherent behaviour have not been found to date and demographic factors such as age, sex or social class have been shown to be poor predictors of adherence (<a href="./references#CD004371-bbs2-0143" title="VermeireE , HearnshawH , Van RoyenP , DenekensJ . Patient adherence to treatment: three decades of research. A comprehensive review. Journal of Clinical Pharmacy and Therapeutics2001;26(5):331-42.">Vermeire 2001</a>). The importance of the person's agreement (<a href="./references#CD004371-bbs2-0123" title="LewisDK , RobinsonJ , WilkinsonE . Factors involved in deciding to start preventive treatment: qualitative study of clinicians' and lay people's attitudes. BMJ2003;327(7419):841-5.">Lewis 2003</a>) and the significance of their role within the doctor‐patient relationship have been emphasised, which has led to replacing the term 'compliance' with more patient‐centred synonyms such as 'adherence' and 'concordance' (<a href="./references#CD004371-bbs2-0123" title="LewisDK , RobinsonJ , WilkinsonE . Factors involved in deciding to start preventive treatment: qualitative study of clinicians' and lay people's attitudes. BMJ2003;327(7419):841-5.">Lewis 2003</a>; <a href="./references#CD004371-bbs2-0126" title="MarinkerM . From Compliance to Concordance: Towards Shared Goals in Medicine taking. London: Royal Pharmaceutical Society of Great Britain, 1997.">Marinker 1997</a>; <a href="./references#CD004371-bbs2-0128" title="MullenPD . Compliance becomes concordance. BMJ1997;314(7082):691-2.">Mullen 1997</a>). The treatment of a symptomless condition such as hyperlipidaemia signifies a particular challenge to both doctor and patient. It has been difficult to identify the scope of the problem, as adherence rates from hyperlipidaemia trials show considerable variation, ranging from 37% to 80%, depending on factors such as study population, background morbidity, classes of drugs, duration of follow‐up and adherence‐measuring methods (<a href="./references#CD004371-bbs2-0142" title="TsuyukiRT , BungardTJ . Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy2001;21(5):576-82.">Tsuyuki 2001</a>). Epidemiological data show that target cholesterol concentrations are achieved in fewer than 50% of people receiving cholesterol‐lowering drugs and that only one in four people continue taking medication in the long term (<a href="./references#CD004371-bbs2-0110" title="BennerJS , GlynnRJ , MogunH , NeumannPJ , WeinsteinMC , AvornJ . Long-term persistence in use of statin therapy in elderly patients. JAMA2002;288(4):455-61.">Benner 2002</a>; <a href="./references#CD004371-bbs2-0133" title="PrimatestaP , PoulterNR . Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ2000;321(7272):1322-5.">Primatesta 2000</a>). Not surprisingly, primary prevention trials appear to have higher discontinuation rates than secondary prevention trials, which indicates a relationship between adherence and awareness of illness (<a href="./references#CD004371-bbs2-0142" title="TsuyukiRT , BungardTJ . Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy2001;21(5):576-82.">Tsuyuki 2001</a>). This was confirmed in a population‐based study involving elderly people, where 60% of people prescribed a statin for acute coronary syndrome gave up treatment within two years, compared to 75% of those without coronary disease (<a href="./references#CD004371-bbs2-0120" title="JackeviciusCA , MamdaniM , TuJV . Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA2002;288(4):462-7.">Jackevicius 2002</a>). </p> <p>A wide range of interventions to improve adherence to medication have been studied (<a href="./references#CD004371-bbs2-0112" title="BrownMT , BussellJK . Medication adherence: WHO cares?Mayo Clinic Proceedings2011;86(4):304-14.">Brown 2011</a>; <a href="./references#CD004371-bbs2-0114" title="CostaE , GiardiniA , SavinM , MendittoE , LehaneE , LaosaO , et al. Interventional tools to improve medication adherence: review of literature. Patient Preference and Adherence2015;9:1303–14.">Costa 2015</a>). They can focus on the person, the drug regimen, the physician or the health system (delivery of medication). Patient education and empowerment is important, as people adhere less to drugs or treatments if they do not understand why they need to take them (<a href="./references#CD004371-bbs2-0112" title="BrownMT , BussellJK . Medication adherence: WHO cares?Mayo Clinic Proceedings2011;86(4):304-14.">Brown 2011</a>). Simplification of the drug regimen may assist, as adherence is inversely related to the number of drugs the person is taking (<a href="./references#CD004371-bbs2-0132" title="PasinaL , BrucatoAL , FalconeC , CucchiE , BrescianiA , SottocornoM , et al. Medication non-adherence among elderly patients newly discharged and receiving polypharmacy. Drugs &amp; Aging2014;31(4):283–9. [DOI: 10.1007/s40266-014-0163-7]">Pasina 2014</a>), and especially complex dosing schedules are at risk. Interventions focused on physicians advocate good communication and a patient‐centred approach (<a href="./references#CD004371-bbs2-0112" title="BrownMT , BussellJK . Medication adherence: WHO cares?Mayo Clinic Proceedings2011;86(4):304-14.">Brown 2011</a>), which could include appropriate follow‐up and support. System‐based approaches could include pharmacist involvement and (automated) patient reminder systems. </p> </section> <section id="CD004371-sec-0012"> <h3 class="title" id="CD004371-sec-0012">How the intervention might work</h3> <p>A number of systematic reviews looking at adherence‐enhancing interventions have been published in the Cochrane Library<i>.</i><a href="./references#CD004371-bbs2-0131" title="NieuwlaatR , WilczynksiN , NavarroT , HobsonN , JefferyR , KeepanasserilA , et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD000011. [DOI: 10.1002/14651858.CD000011.pub4]">Nieuwlaat 2014</a> identified effective ways to improve medication adherence for a variety of medical conditions in widely differing populations. Adherence to short‐term drug treatment was improved by written information, personal phone calls and counselling. For long‐term treatments, no simple intervention and only some complex ones led to some improvement in health outcomes (<a href="./references#CD004371-bbs2-0131" title="NieuwlaatR , WilczynksiN , NavarroT , HobsonN , JefferyR , KeepanasserilA , et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD000011. [DOI: 10.1002/14651858.CD000011.pub4]">Nieuwlaat 2014</a>). <a href="./references#CD004371-bbs2-0139" title="SchroederK , FaheyT , EbrahimS . Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD004804. [DOI: 10.1002/14651858.CD004804]">Schroeder 2004</a> focused on medications for controlling blood pressure and reported enhanced adherence by reducing the number of daily doses. Patient support and education interventions improved adherence to antiretroviral therapy when targeting practical medication management skills aimed at individuals rather than groups (<a href="./references#CD004371-bbs2-0136" title="RuedaS , Park-WyllieLY , BayoumiA , Tynan A-M, AntoniouT , RourkeS , et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database of Systematic Reviews2006, Issue 3. Art. No: CD001442. [DOI: 10.1002/14651858.CD001442.pub2]">Rueda 2006</a>). In the treatment of type 2 diabetes, it was concluded that nurse‐led interventions, home aids, diabetes education and pharmacy‐led interventions do not show significant effects (<a href="./references#CD004371-bbs2-0144" title="VermeireEIJJ , WensJ , Van RoyenP , BiotY , HearnshawH , LindenmeyerA . Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD003638. [DOI: 10.1002/14651858.CD003638.pub2]">Vermeire 2005</a>). Another review concluded that reminder packaging increased the proportion of people taking their medications, but the effect was not large (<a href="./references#CD004371-bbs2-0125" title="MahtaniKR , HeneghanCJ , GlasziouPP , PereraR . Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD005025. [DOI: 10.1002/14651858.CD005025.pub3]">Mahtani 2011</a>). </p> </section> <section id="CD004371-sec-0013"> <h3 class="title" id="CD004371-sec-0013">Why it is important to do this review</h3> <p>The indication for prescribing lipid‐lowering drugs has changed substantially over the last 20 years (<a href="./references#CD004371-bbs2-0105" title="StoneNJ , RobinsonJG , LichtensteinAH , Bairey MerzCN , BlumCB , et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsA Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014;129(25 Suppl 2):s1-45.">ACC/AHA Guidelines 2013</a>; <a href="./references#CD004371-bbs2-0109" title="BaigentC , KeechA , KearneyPM , BlackwellL , BuckG , PollicinoC , et al, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet2005;366(9493):1267-78.">Baigent 2005</a>). With evidence to suggest that effectiveness of statins occurs irrespective of initial lipid level, greater numbers of people are being actively prescribed lipid‐lowering agents. Observational studies have shown that adherence to lipid‐lowering drugs is poor, with people taking their medication only 60% of the time in a one‐year period (<a href="./references#CD004371-bbs2-0108" title="AvornJ , MonetteJ , LacourA , BohnRL , MonaneM , MogunH , et al. Persistence of use of lipid-lowering medications. JAMA1998;279(18):1458-62.">Avorn 1998</a>). There is strong evidence that adherence diminishes over time in people who are being treated as part of a primary or secondary prevention strategy (<a href="./references#CD004371-bbs2-0110" title="BennerJS , GlynnRJ , MogunH , NeumannPJ , WeinsteinMC , AvornJ . Long-term persistence in use of statin therapy in elderly patients. JAMA2002;288(4):455-61.">Benner 2002</a>; <a href="./references#CD004371-bbs2-0120" title="JackeviciusCA , MamdaniM , TuJV . Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA2002;288(4):462-7.">Jackevicius 2002</a>). The consequence of inadequate adherence to lipid‐lowering therapy is substantial. In secondary prevention, inadequate adherence is associated with an increase in recurrent myocardial infarction and all‐cause mortality (<a href="./references#CD004371-bbs2-0145" title="WeiL , WangJ , ThompsonP , WongS , StruthersAD , MacDonaldTM . Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart (British Cardiac Society)2002;88(3):229-33.">Wei 2002</a>). For these reasons, it is important that clinically effective and cost‐effective strategies to improve adherence are found for primary and secondary prevention of cardiovascular disease in the community. The findings of our review can be integrated into clinical practice guidelines and assist clinicians in making a difference to patient outcomes. This update of previous reviews, published in 2004 and updated in 2010 (<a href="./references#CD004371-bbs2-0148" title="SchedlbauerA , SchroederK , PetersTJ , FaheyT . Interventions for improving adherence to lipid lowering medication. Cochrane Database of Systematic Reviews2004, Issue 4. Art. No: CD004371. [DOI: 10.1002/14651858.CD004371.pub2]">Schedlbauer 2004</a>; <a href="./references#CD004371-bbs2-0149" title="SchedlbauerA , DaviesP , FaheyT . Interventions to improve adherence to lipid lowering medication. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD004371. [DOI: 10.1002/14651858.CD004371.pub3]">Schedlbauer 2010</a>), assessed interventions designed to help people take their lipid‐lowering medication in an ambulatory care setting, taking into account new and emerging evidence. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004371-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004371-sec-0014"></div> <p>To assess the effects of interventions aimed at improving adherence to lipid‐lowering drugs, focusing on measures of adherence and clinical outcomes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004371-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004371-sec-0015"></div> <section id="CD004371-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004371-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), of parallel‐group or cross‐over design, that used individual or cluster randomisation. </p> </section> <section id="CD004371-sec-0018"> <h4 class="title">Types of participants</h4> <p>All adults (over 18 years of age) who were prescribed lipid‐lowering medication for primary or secondary prevention of cardiovascular disease in ambulatory care settings. </p> </section> <section id="CD004371-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Interventions of any type intended to increase adherence to self‐administered lipid‐lowering medication versus usual care or no intervention. </p> <p>This included, but was not exclusive to, interventions such as:</p> <p> <ol id="CD004371-list-0001"> <li> <p>simplification of drug regimen;</p> </li> <li> <p>patient education and information;</p> </li> <li> <p>intensified patient care (increased follow‐up, sending out reminders, etc.);</p> </li> <li> <p>complex behavioural approaches (increasing motivation by arranging group sessions, giving out rewards, etc.); </p> </li> <li> <p>decision support systems (computer‐based information systems aimed at support of decision‐making);</p> </li> <li> <p>administrative improvements (audit, documentation, computers, co‐payments);</p> </li> <li> <p>large‐scale pharmacy‐led automated telephone intervention.</p> </li> </ol> </p> </section> <section id="CD004371-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD004371-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>Methods of measuring adherence continue to be widely variable and remain controversial. We identify three categories of adherence assessment, and have included them in this review: </p> <p> <ol id="CD004371-list-0002"> <li> <p>Indirect measures of adherence (e.g. pill count, prescription refill rate, electronic monitoring); </p> </li> <li> <p>Subjective measures of adherence (e.g. person's self‐report in diaries, interviews);</p> </li> <li> <p>Direct measures of adherence (tracer substances in blood or urine).</p> </li> </ol> </p> </section> <section id="CD004371-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>We have also included the following outcome measures, in addition to adherence measures:</p> <p> <ol id="CD004371-list-0003"> <li> <p>Physiological indicators (e.g. total cholesterol);</p> </li> <li> <p>Health outcome indications (e.g. quality of life, morbidity, mortality);</p> </li> <li> <p>Adverse effects;</p> </li> <li> <p>Implications for costs (impact of intervention on economic outcomes, economic evaluation).</p> </li> </ol> </p> <p>In the literature, physiological indicators, health outcomes and adverse effects have been used as proxy measures for adherence. We included these studies only if those indicators were reported in association with adherence outcomes (see <a href="./references#CD004371-sec-0108" title="">Characteristics of included studies</a>). </p> </section> </section> </section> <section id="CD004371-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004371-sec-0024"> <h4 class="title">Electronic searches</h4> <p><b>Previous searches</b> </p> <p>The 2010 version of this review included searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2008, Issue 1), MEDLINE (January 2000 to March 2008), Embase (January 1998 to March 2008), PsycINFO (1972 to March 2008) and CINAHL (January 1982 to March 2008). CENTRAL incorporates all controlled trials from Embase and MEDLINE, except in the most recent years. We used an appropriate RCT filter for MEDLINE (<a href="./references#CD004371-bbs2-0115" title="DickersinK , SchererR , LefebvreC . Identifying relevant studies for systematic reviews. BMJ1994;309(6964):1286-91.">Dickersin 1994</a>) and Embase (<a href="./references#CD004371-bbs2-0121" title="LefebvreC , McDonaldS . Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. In: Paper presented at the Fourth International Cochrane Colloquium, 20-24 Oct 1996; Adelaide, Australia. 1996.">Lefebvre 1996</a>). Details of the previous search strategies are in <a href="./appendices#CD004371-sec-0081">Appendix 1</a> and <a href="./appendices#CD004371-sec-0087">Appendix 2</a>. </p> <p><b>Latest Searches</b> </p> <p>For this updated review we included the studies from the previously published review (<a href="./references#CD004371-bbs2-0149" title="SchedlbauerA , DaviesP , FaheyT . Interventions to improve adherence to lipid lowering medication. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD004371. [DOI: 10.1002/14651858.CD004371.pub3]">Schedlbauer 2010</a>; search date 31 March 2008). We updated the search terms to increase the sensitivity of the searches. We applied these changes and reran the searches from database inception. We subsequently applied limits to entry dates or equivalent to all databases except CENTRAL, to identify only those records which had been added to the databases since the last search in 2008. </p> <p>We ran the most recent database search on 3 February 2016 and included the following databases: </p> <p> <ul id="CD004371-list-0004"> <li> <p>CENTRAL in the Cochrane Library (Issue 1, 2016)</p> </li> <li> <p>MEDLINE (Ovid, 1946 to January Week 3 2016)</p> </li> <li> <p>Embase (Ovid, 1980 to Week 5 2016)</p> </li> <li> <p>PsycINFO (Ovid, 1806 to January Week 4 2016)</p> </li> <li> <p>CINAHL Plus with Full Text (EBSCO, 1937 to 3 February 2016).</p> </li> </ul> </p> <p>We also searched clinical trials registers (<a href="http://www.anzctr.org.au/" target="_blank">www.anzctr.org.au/</a> and <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>) up to 27 July 2016, using the following search terms: "statin", "adherence", "compliance", "intervention". </p> <p>We updated the RCT filters for MEDLINE and Embase according to the latest recommendations in the <i>Cochrane Handbook</i> (<a href="./references#CD004371-bbs2-0122" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>), and applied adaptations of it to the other databases, except for CENTRAL. Details of the latest search strategies are in <a href="./appendices#CD004371-sec-0093">Appendix 3</a>. We applied no language restrictions. </p> </section> <section id="CD004371-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We sought additional studies through scrutinising the reference lists of identified eligible studies. </p> </section> </section> <section id="CD004371-sec-0026"> <h3 class="title" id="CD004371-sec-0026">Data collection and analysis</h3> <section id="CD004371-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Three review authors (JS, MM, and RU) selected studies independently by assessing titles and abstracts. We obtained full‐text articles of potentially relevant studies. Following this initial screening, the three review authors (JS, MM, RU) selected trials independently by applying predetermined inclusion criteria. We included a trial if it met all of our inclusion criteria. The review authors discussed disagreements and resolved them, with recourse to MVD and RD when necessary. We used a spreadsheet to identify and extract studies in duplicate. </p> </section> <section id="CD004371-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We extracted study outcome data using a predefined data collection tool that had been developed by one of the review authors (MVD). The form had been developed and piloted on a random sample of three studies and refined appropriately. For this updated version of the review, we conducted the 'Risk of bias' assessment for all included studies with Review Manager 5. Three review authors (JS, MM, and RU) extracted data from the newly‐selected studies, with a second author checking the extracted data for accuracy. </p> </section> <section id="CD004371-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We performed 'Risk of bias' assessment using the Cochrane 'Risk of bias' tool in the Cochrane Handbook of Systematic Reviews of Interventions (<a href="./references#CD004371-bbs2-0119" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Handbook of Systemtic Reviess of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We assessed the following 'Risk of bias' categories: </p> <p> <ul id="CD004371-list-0005"> <li> <p><b>selection bias</b> (by assessing the method of random number generation and the process of allocation concealment); </p> </li> <li> <p><b>performance and detection bias</b> (blinding of participants, providers and outcomes assessors); </p> </li> <li> <p><b>attrition bias</b> (by assessing how incomplete data were managed); and </p> </li> <li> <p><b>reporting bias</b> (by assessing whether all intended outcomes were reported). </p> </li> </ul> </p> <p>See <a href="#CD004371-sec-0051">Risk of bias in included studies</a>. We rated each of the studies as 'high risk', 'low risk' or 'unclear risk' for each of these risk of bias domains. We also took into consideration the method used to measure adherence, as some methods are more likely to be biased than others (see <a href="./references#CD004371-sec-0108" title="">Characteristics of included studies</a>). For instance, medication refill data are likely to measure adherence more objectively than manual pill counts, even if outcome assessors are not blinded to group allocation. We applied a judgement of ‘unclear risk’ to blinding where participant and physician were not blinded. We applied a judgement of ‘unclear risk’ to blinding where outcome assessors were not blinded. We also applied a judgement of ‘unclear risk’ to any risk assessment when information was not provided or if there was insufficient information to permit a judgement. </p> </section> <section id="CD004371-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we reported the results as odds ratios (ORs) with 95% confidence intervals (CIs). For continuous data, we reported the mean difference (MD) with standard deviation (SD) of pre‐ and post‐measurements. For serum cholesterol, we report values in mg/dL. We converted cholesterol values reported as mmol/L to mg/dL, using the formula: 1 mmol/l = 38.66976 mg/dL. </p> </section> <section id="CD004371-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis in our meta‐analysis was the participant; however, if this was not the case, such as in cluster‐randomised trials, we planned to make adjustment for clustering in the pooled analysis following the guidelines in the <i>Cochrane Handbook</i> (<a href="./references#CD004371-bbs2-0119" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Handbook of Systemtic Reviess of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD004371-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>If data for analysis were missing, we attempted to obtain information from authors. If no additional data were provided by the authors we used available‐case analysis, which includes analysis of the available data only (thus ignoring the missing data), assuming that the data were missing at random. </p> </section> <section id="CD004371-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the data analysis tools in Review Manager 5 for the assessment of heterogeneity, which is indicated in the forest plots measuring the treatment effect. We assessed heterogeneity by first assessing the comparability of the included studies in terms of population, setting and outcomes (face value or "clinical" heterogeneity). We considered pooling only studies that were sufficiently similar from a clinical perspective. We assessed statistical heterogeneity by calculating the Chi<sup>2</sup> statistic (with P value &lt; 0.10 as level of significance) and the I<sup>2</sup> statistic. </p> <p>We used I<sup>2</sup> thresholds as described in the <i>Cochrane Handbook</i> as a rough guide to interpretation as follows (<a href="./references#CD004371-bbs2-0119" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Handbook of Systemtic Reviess of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), and used 40% as a cut‐off value for important heterogeneity, which means that we considered an I<sup>2</sup> under 40% heterogeneity as low: </p> <p>• 0% to 40%: might not be important;<br/>• 30% to 60%: may represent moderate heterogeneity;<br/>• 50% to 90%: may represent substantial heterogeneity;<br/>• 75% to 100%: considerable heterogeneity. </p> </section> <section id="CD004371-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>If we suspected reporting bias, we contacted the authors to request missing data. As the number of studies available for meta‐analysis was fewer than 10 we did not investigate publication bias by means of a funnel plot. </p> </section> <section id="CD004371-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We grouped the studies according to the type of intervention. In the absence of an existing standard classification for such interventions, the review authors agreed upon a classification based on the pragmatic focus of the intervention. For instance, we considered interventions related to the medication regimen separate from the behavioural approaches involving doctors or other healthcare professionals. We identified seven types of interventions and reported them separately: </p> <p> <ol id="CD004371-list-0006"> <li> <p>Simplification of drug regimen;</p> </li> <li> <p>Patient education and information;</p> </li> <li> <p>Intensified patient care;</p> </li> <li> <p>Complex behavioural approaches;</p> </li> <li> <p>Decision support systems;</p> </li> <li> <p>Administrative improvements; and</p> </li> <li> <p>Pharmacy‐led interventions.</p> </li> </ol> </p> <p>'Usual care' was not defined as a separate intervention. We compared outcomes for each comparison independently, and performed pooling of data and meta‐analysis where possible. We chose a per‐protocol analysis, as intention‐to‐treat analysis would yield misleading results by not showing an effect in many of these studies due to the pragmatic nature of the study designs. We pooled data by using the random‐effects model. We also performed a fixed‐effect model analysis if we assessed statistical heterogeneity as low (I<sup>2</sup> &lt; 40%). We used dichotomous outcomes for analysis of medication adherence, and continuous outcomes for analysis of clinical markers. </p> <p>We included the cross‐over trial (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>) from the previous version of this review. However, we classified this study as a simplification of drug regimen intervention and could not perform pooling of data and meta‐analysis. Thus, we did not include it in our meta‐analysis for intensified patient care versus usual care. </p> </section> <section id="CD004371-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not plan any subgroup analyses for this review.</p> </section> <section id="CD004371-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analysis for the pooled results by removing the studies that contributed to heterogeneity and comparing the overall outcome estimate. We also compared the results of pooling with a random‐effects model to those using a fixed‐effect model when statistical heterogeneity was low (I<sup>2</sup> &lt; 40%, see <a href="#CD004371-sec-0033">Assessment of heterogeneity</a>), in order to assess the robustness of the effect estimate. We performed sensitivity analysis for the impact of high attrition on the overall study outcome by removing the studies with high attrition (&gt; 20%). </p> </section> <section id="CD004371-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a Summary of findings table using the following outcomes ‐ medication adherence, reduction in LDL‐C and reduction in total serum cholesterol<i>.</i> We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD004371-bbs2-0118" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924-6.">Guyatt 2008</a>). We used methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (<a href="https://archie.cochrane.org/sections/documents/view?version=z1609271417383349474320243100796&amp;format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>) using GRADEpro software (<a href="https://gradepro.org/" target="_blank">https://gradepro.org/</a>). We justified all decisions to downgrade the quality of studies using footnotes. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004371-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004371-sec-0039"></div> <section id="CD004371-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD004371-sec-0041"> <h4 class="title">Results of the search</h4> <p>The search for the original 2004 review of this topic retrieved 2380 articles from all sources (<a href="./references#CD004371-bbs2-0148" title="SchedlbauerA , SchroederK , PetersTJ , FaheyT . Interventions for improving adherence to lipid lowering medication. Cochrane Database of Systematic Reviews2004, Issue 4. Art. No: CD004371. [DOI: 10.1002/14651858.CD004371.pub2]">Schedlbauer 2004</a>). Eight studies met all inclusion criteria and were analysed. The search for the first update in 2010 (<a href="./references#CD004371-bbs2-0149" title="SchedlbauerA , DaviesP , FaheyT . Interventions to improve adherence to lipid lowering medication. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD004371. [DOI: 10.1002/14651858.CD004371.pub3]">Schedlbauer 2010</a>) identified three additional studies from the 4227 screened records. </p> <p>The updated search in January 2015 retrieved 6785 articles from all sources. After de‐duplication, we reviewed 5768 titles. Of these references, we excluded 5734 studies by identifying titles and abstracts which did not meet the study criteria for inclusion. We added 16 new studies to the 2010 review. The updated search in February 2016 retrieved 6719 articles from all sources. We reviewed these articles and excluded those which, on the basis of title and abstracts, did not meet the study criteria for inclusion. We added five new studies. One study that was previously excluded was reconsidered and included (<a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>). We reviewed three other studies also identified in previous searches and originally excluded, and these are awaiting classification (<a href="./references#CD004371-bbs2-0099" title="JohnsonSS , DriskellMM , JohnsonJL , DymentSJ , ProchaskaJO , ProchaskaJM , et al. Transtheoretical model intervention for adherence to lipid-lowering drugs. Disease Management2006;9(2):102-14. ">Johnson 2006</a>; <a href="./references#CD004371-bbs2-0098" title="HarrisonTN , GreenKR , LiuIA , VansomphoneSS , HandlerJ , ScottRD , et al. Automated outreach for cardiovascular-related medication refill reminders. Journal of Clinical Hypertension2015;18(7):641-6. [DOI: 10.1111/jch.12723]ReynoldsK , GreenKR , VansomphoneSS , ScottRD , CheethamTC . Automated outreach for cholesterol-lowering medication refill reminders. European Heart Journal2011;32(Abstract Suppl):230-1. ">Harrison 2015</a>; <a href="./references#CD004371-bbs2-0100" title="LeeJK . Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA2006;296(21):2563-71. ">Lee 2006</a>). </p> <p>The search in the clinical trials registers retrieved eight references. We identified and included two additional studies (<a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>) and included two others as ongoing studies (<a href="./references#CD004371-bbs2-0102" title="ACTRN12616000422426. Text4Heart Partnership: a text messaging program to enhance self-management of cardiovascular disease. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370398 1st April 2016. ">ACTRN12616000422426</a>; <a href="./references#CD004371-bbs2-0101" title="ACTRN12616000233426. INtegrated combination Therapy, Electronic General practice support tool, phaRmacy led intervention And combination Therapy Evaluation (INTEGRATE): A pragmatic cluster randomised controlled trial. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370068 19th February 2016. ">ACTRN12616000233426</a>). We identified the protocol of another ongoing study in the 2016 search (<a href="./references#CD004371-bbs2-0103" title="ThomS , FieldJ , PoulterN , PatelA , PrabhakaranD , StantonA , et al. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. European Journal of Preventive Cardiology2014;21:252-61. ">Thom 2014</a>). </p> <p>We summarise the search results in <a href="#CD004371-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD004371-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004371-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD004371-sec-0042"> <h4 class="title">Included studies</h4> <p>This review includes 35 references to 35 studies. The study sizes varied from 30 (<a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>) to 861,894 (<a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>) with a total of 919,316 participants included in the review. Most trials included both men and women. Two trials included only men (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>)<i>.</i> Mean age ranged from 49 to 76.5 years and was not reported in three studies (<a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>). There was great variation in the types of participants, setting, medication, interventions used and outcomes measured. This is described in more detail in the <a href="./references#CD004371-sec-0108" title="">Characteristics of included studies</a> table. Among the included studies, one study (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>) was identified as a cross‐over trial and five studies (<a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a>; <a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>) as cluster‐RCTs. </p> <p>See <a href="./references#CD004371-sec-0108" title="">Characteristics of included studies</a>. </p> <section id="CD004371-sec-0043"> <h5 class="title">Interventions</h5> <p>We stratified interventions into groups on pragmatic grounds, as generally accepted categories do not exist. We identified seven main groups: </p> <p> <ol id="CD004371-list-0007"> <li> <p>Drug regimen simplification (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>); </p> </li> <li> <p>Patient education and information (<a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>; <a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; <a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>); </p> </li> <li> <p>Intensified patient care with reminders via mail, telephone and hand‐held pill devices (<a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; <a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>; <a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>; <a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>; <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>; <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>; <a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>; <a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>; <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>); </p> </li> <li> <p>Complex behavioural approaches, group sessions (<a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>); </p> </li> <li> <p>Decision support systems (<a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>); </p> </li> <li> <p>Administrative improvements (<a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>; <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a>); </p> </li> <li> <p>Large‐scale pharmacy‐led automated telephone intervention (<a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>); <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a>). </p> </li> </ol> </p> <p><i>Drug regimen simplification</i> was described as using a formulation (e.g. slow release) that could be given twice rather than four times a day (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>), or a fixed dose formulation such as a 'polypill' or other (<a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>). </p> <p><i>Patient education and information</i> was in the form of educative text messages delivered to participants (<a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>), a 'Program Kit', including a videotape, information booklet, and newsletter (<a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>), videotapes mailed to participants (<a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>), or a pack containing a videotape, an educational leaflet, details of the free phone patient helpline and website, and labels with a reminder to take study medication, in addition to regular personalised letters and phone calls (<a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>). In <a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a> the community pharmacist reviewed the participant monthly when they collected their prescriptions, and at three and six months the pharmacist had a longer discussion with the participant, tailored to their assessed medication beliefs. </p> <p><i>Intensified patient care</i> was delivered by different healthcare providers. Interventions involving pharmacists included counselling visits at the pharmacy (<a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>), phone calls by a pharmacist (<a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>), pharmacist‐led voice messaging (educational and medication refill reminder calls) (<a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>), a computer‐based tracking system and a series of co‐ordinated patient‐centred pharmacist‐delivered telephone counselling contacts (<a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>), and review by the participants’ pharmacist and a ‘beep‐card’ to remind the participant of the dosing time (<a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>). Nurses were involved in two studies: counselling from a nurse and an adherence tip sheet (<a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>), and multifactorial risk‐factor counselling by a nurse practitioner (<a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>). Doctor‐led counselling was delivered in two studies as counselling and advice about the disease, medicine, medicine use, adherence and lifestyle measures (<a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>), counselling every eight weeks (<a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>). Other interventions included automated telephone calls followed by letters (<a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>), telephone reminders and reminder postcards (<a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>), telephone call reminders (<a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>), a calendar reminder (<a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>), telephone calls (<a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>), and text messages using an automated computer programme (<a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>) or sent live (<a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a>). </p> <p><i>Complex behavioural approaches</i> were used by <a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a> and consisted of a group session of 90 minutes for a maximum of 15 participants at a time, educating them about hypercholesterolaemia, followed by monthly letters written by the same clinician who delivered the group sessions with reinforcing messages. <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a> used medication adherence information given by physicians and motivational interviewing by trained staff (nurses, pharmacists). </p> <p><i>Decision support systems</i> consisted of an electronic reminder device (ERD) that started beeping every day at the same time until the participant switched it off (<a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>). </p> <p><i>Administrative improvements:</i> in <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a> the physician was provided with the participant's drug profile which included the total costs of medications dispensed each month, the amount of out‐of‐pocket expenditure paid by the participant, a graphic representation of unfilled prescriptions, and days of drug supply for each medication. Then at each visit the participant's adherence was calculated and if treatment adherence was less than 80%, the physician received an alert to check with the participant. In <a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a> medication co‐payments for participants in the intervention group were waived at the point of care (i.e. pharmacy), whereas participants in the control group continued to pay their usual copayments when refilling their prescriptions. </p> <p><i>Large‐scale pharmacy‐led automated telephone intervention</i> was delivered entirely by the pharmacy in <a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>. In the first intervention, the 'automated intervention' participants received automated phone calls on days three and seven to remind them that their prescription was ready for them to pick up if the prescription had been processed by the pharmacy but the participant had not collected it. In the subsequent 'live intervention' a pharmacist or technician called participants who had not collected their prescription despite the reminders. The calls aimed to better understand why participants were not taking their medication and to counsel them regarding appropriate medication use. <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a> used automated <i>Interactive Voice Recognition (IVR) Calls</i> to participants when they were due or overdue for a refill. Speech‐recognition technology was used in these calls to educate participants about their medications. </p> </section> <section id="CD004371-sec-0044"> <h5 class="title">Medication</h5> <p>The lipid‐lowering medications used to treat hyperlipidaemia in most trials were statins (3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A (HMG‐CoA) reductase inhibitors) (<a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>; <a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; <a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>; <a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a><a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>; <a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>; <a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>; <a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>; <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>; <a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>; <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>; <a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; <a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>; <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a>; <a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>; <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>; <a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>). Anion‐exchange resins or bile acid sequestrants were used in five trials (<a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>; <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>). Niacin or nicotinic acid were used in three trials (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>). Two trials used a combined medication regimen (<a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>), and two trials did not specify a lipid‐lowering medication (<a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a>). Drug therapy was most commonly started after study allocation; only eight studies included participants who were already taking lipid‐lowering medication (<a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a>; <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>). </p> </section> <section id="CD004371-sec-0045"> <h5 class="title">Cardiovascular risk</h5> <p>Most studies included in this review enrolled participants at high risk of suffering a cardiovascular event, where lipid‐lowering medication was used for primary prevention, whether or not serum cholesterol levels were high (<a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>; <a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; <a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>; <a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>; <a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>; <a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>; <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>; <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a>; <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>). Nine trials included participants with pre‐existing cardiovascular pathology, thus taking medication for secondary prevention (<a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>; <a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>; <a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>; <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>; <a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>; <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a>). The remaining studies looked at people on medication for both primary and secondary prevention (<a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>; <a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>; <a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>). One study (<a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>) identified people at a community pharmacy and did not indicate whether the medication was for primary or secondary prevention. </p> </section> <section id="CD004371-sec-0046"> <h5 class="title">Settings</h5> <p>Twelve of the included trials took place in primary care (<a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>; <a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>; <a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>; <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a>; <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>; <a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>). In six studies participants were followed up in secondary care (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; <a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>), and three studies took place in both settings (<a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>). Other settings were community pharmacies (<a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>; <a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>; <a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>), healthcare system (<a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>), health maintenance organisation (<a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a>), and Veterans Affairs medical centres (<a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>). Trials were set geographically in the USA (15 trials), Netherlands (four trials), Australia (three trials), Spain (three trials), Canada (two trials), England (two trials), Poland (one trial), New Zealand (one trial), India (one trial), China (one trial), Ireland (one trial), and Belgium (one trial). The FOCUS, ORBITAL and PILL trials were conducted across several countries. FOCUS: Argentina, Paraguay, Italy, Spain (<a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>); ORBITAL: Germany, Denmark, Switzerland, and Greece (<a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>); PILL: Australia, Brazil, India, Netherlands, New Zealand, United Kingdom, United States (<a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>). </p> </section> <section id="CD004371-sec-0047"> <h5 class="title">Follow‐up</h5> <p>Follow‐up times ranged from no follow‐up to 24 months of follow‐up. Most studies achieved their end point outcomes at nine months beginning at three‐month intervals. The frequency of the intervention varied, ranging from one single contact up to 12 (see <a href="./references#CD004371-sec-0108" title="">Characteristics of included studies</a> table). </p> </section> <section id="CD004371-sec-0048"> <h5 class="title">Outcome measures</h5> <p>The methods used to measure adherence included self‐report, Medication Adherence Report Scale (MARS), time to discontinuation, medication possession ratio (MPR), proportion of days covered (PDC), continuous multiple interval (CMI), Medication Event Monitoring System (MEMS), drug profile review, prescription refill rate, prescription abandonment, and pill count. Self‐report was assessed by asking participants if they had taken their medication as prescribed and how many doses they missed over a given time period (<a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>; <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>, <a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>). The MARS questionnaire was used in two studies (<a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>). Time to discontinuation of lipid‐lowering medication was used by three studies (<a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>). MPR is defined as the number of days on medication after study enrolment divided by the number of days between the first fill and the last refill plus the day's supply of last refill. MPR was used in six studies (<a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>; <a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>). PDC was used in three studies (<a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>; <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a>). CMI, the ratio of days supply obtained to total days between refill records, was based on pharmacy records from one study (<a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>). MEMS is an electronic system of standard pill bottles with microprocessors in the cap that record the timing and frequency of bottle openings, providing detailed and reliable outcome measures at low risk of bias. MEMS was used in three trials (<a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>; <a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>; <a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>). Drug profile review by a physician on each visit with study participants was used in one study (<a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a>). Prescription refill rates were used by seven studies, where refill information was obtained from pharmacies (<a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>). Prescription abandonment was used in one study (<a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>). Manual pill counting was performed in seven trials (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>; <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>). Counting pills is a measure vulnerable to participant manipulation, and one author attempted to increase the reliability of this method by performing unexpected visits to participants' homes for pill counts (<a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>). In another study, pills were not counted in the participant's view in order to avoid influencing their subsequent adherent behaviour (<a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>). The different methods of measuring adherence was one of the main obstacles in comparing results from the studies, which was further complicated by the fact that some authors used more than one method to measure adherence during their trials. </p> <p>The report of percentage of mean compliance was considered as the most valid description of compliant behaviour and is reported in the tables of included studies as a main outcome measure, providing the opportunity of comparison between the studies. Other outcome measures reported were: thresholds to define compliant behaviour, i.e. the proportion of participants taking more than 80% of the prescribed medication; discontinuation rates; absolute risk reduction; relative risk reduction; and number needed to intervene in order to save one non‐adherent behaviour (see <a href="./references#CD004371-sec-0108" title="">Characteristics of included studies</a> table). </p> <p>Serum lipids consisting of total cholesterol, HDL, LDL and triglycerides are physiological indicators of participant compliance that were the most frequently reported outcome in the following trials: <a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>; <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>; <a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>; <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>; <a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>; <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a>; <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>; <a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>. Some trials began with a 'start‐up' phase where participants were either taking medication (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>) or following a diet (<a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>) before baseline blood samples were taken; the majority of the trials took baseline blood samples immediately after recruitment. Other reported outcome measures included side effects experienced (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>; <a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>), participant satisfaction (<a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>), and self‐reported lifestyle measures (<a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>; <a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>). None of the studies provided data on morbidity or mortality as additional outcome measures. </p> </section> <section id="CD004371-sec-0049"> <h5 class="title">Commercial sponsorship</h5> <p>Authors declared some form of funding by drug companies in <a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; <a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>; <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>; <a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>; <a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>; <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>; <a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>. </p> </section> </section> <section id="CD004371-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We excluded 62 studies after review (see <a href="./references#CD004371-sec-0109" title="">Characteristics of excluded studies</a>). The most common reason for exclusion was that the study was not aimed at improving adherence. One article was a study description without any outcomes and appeared to be the same as <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>, which we included for analysis; however, the two studies had different trial registration numbers. </p> </section> </section> <section id="CD004371-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>The results of the 'Risk of bias' analysis are shown in <a href="#CD004371-fig-0002">Figure 2</a>; <a href="#CD004371-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD004371-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD004371-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <div class="figure" id="CD004371-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004371-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD004371-sec-0052"> <h4 class="title">Allocation</h4> <p>We rated 11 studies at 'unclear risk' for random sequence generation, as they did not provide sufficient information to make a judgement (<a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>; <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>; <a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>; <a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>; <a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>). We assessed 24 studies at 'low risk' for random sequence generation, as they reported using a computer‐generated allocation process, telephone allocation, or allocation by a statistician who was not involved in conducting the study (<a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>; <a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; <a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>; <a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>; <a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>; <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>; <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>; <a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; <a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>; <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a>; <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>; <a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>). We rated none of the studies at 'high risk' for random sequence generation. </p> <p>We assessed 14 studies at 'unclear risk' for allocation concealment, as they did not report sufficient information to allow judgement. (<a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>; <a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>; <a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>; <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>) We rated 20 studies at 'low risk' for allocation concealment as this was adequately described and deemed appropriate (<a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; <a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a>; <a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>; <a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>; <a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>; <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>; <a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>; <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>; <a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; <a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>; <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a>; <a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>). In <a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a> allocation was not concealed as reported in the protocol of the study (ACTRN12611000322932), so we judged this to be at 'high risk' for allocation concealment. </p> </section> <section id="CD004371-sec-0053"> <h4 class="title">Blinding</h4> <p>One study (<a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a>) had a single‐blinded study design and was rated as 'high risk'. Physicians and participants were blind to the outcome assessed, but not to the intervention in this study. We assessed 28 studies as being at 'unclear risk', as they had an unblinded, open‐label study design or did not report open‐label design (<a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>; <a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>; <a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>; <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>; <a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>; <a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>; <a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>; <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>; <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>; <a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; <a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>; <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a>; <a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>; <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a>). Five studies at low risk stated a method where investigators and participants were blind to the outcome and intervention (<a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; <a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>). Blinding participants to the intervention they were receiving and blinding key study personnel including physicians was often not possible, given the nature of the intervention. Most trials did not report blinding of those assessing the outcome 'adherence'. </p> </section> <section id="CD004371-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>We judged two studies (<a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>; <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>) as being at 'high risk' for attrition bias, due to a high rate of attrition in return of a survey tool (<a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>) or high attrition (31.5%) at the primary end point after 12 months follow‐up (<a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>). We rated six studies as being at 'unclear risk' due to variable rates of study attrition (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>; <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a>; <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a>) or not reporting on attrition (<a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>). We judged the other studies as being at 'low risk', as they reported minimal to no loss to follow‐up. </p> </section> <section id="CD004371-sec-0055"> <h4 class="title">Selective reporting</h4> <p>All included studies reported on all intended outcomes, as assessed by comparing the Methods section with the Results section or with the available protocol. </p> </section> </section> <section id="CD004371-sec-0056"> <h3 class="title" id="CD004371-sec-0056">Effects of interventions</h3> <p>See: <a href="./full#CD004371-tbl-0001"><b>Summary of findings 1</b> Summary of findings table for the comparison of 'intensified patient care' vs 'usual care'</a> </p> <section id="CD004371-sec-0057"> <h4 class="title">Types of interventions</h4> <p>The trials in this review aimed to increase adherence to lipid‐lowering medication by applying one of the following seven intervention categories. In order to determine study similarities, we created a grid into which we placed studies with similar interventions and comparators. We then further grouped those studies which we found to have both similar interventions and comparators, according to similar outcome measures. In grouping the studies in this manner, we found that there were sufficient studies to conduct a meta‐analysis among those studies comparing such interventions with usual care (see <a href="#CD004371-tbl-0002">Table 1</a>). </p> <div class="table" id="CD004371-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Matrix of comparisons in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Comparator intervention</b> </p> </td> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1) simplification of drug regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>2) patient education and information</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>3) intensified patient care<sup>1</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>4) complex behavioural approaches<sup>2</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>5) decision support systems<sup>3</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>6) administrative improvements<sup>4</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>7) pharmacy‐led intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1) simplification of drug regimen</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>2) patient education and information</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>3) intensified patient care<sup>1</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>4) complex behavioural approaches<sup>2</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>; </p> <p><a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>5) decision support systems<sup>3</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>6) administrative improvements<sup>4</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>7) pharmacy‐led intervention</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>8) usual care/placebo</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; </p> <p><a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; </p> <p><a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; </p> <p><a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; </p> <p><a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; </p> <p><a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>; </p> <p><a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>; </p> <p><a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>; </p> <p><a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; </p> <p><a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; </p> <p><a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; </p> <p><a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; </p> <p><a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; </p> <p><a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a><a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>; </p> <p><a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>; <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>; </p> <p><a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; </p> <p><a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>; </p> <p><a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; </p> <p><a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>; </p> <p><a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>; </p> <p><a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>; <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>; <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Intensified patient care includes increased follow‐up, sending out reminders, etc.<br/><sup>2</sup> Complex behavioural approaches include increasing motivation by arranging group sessions, giving out rewards, etc.<br/><sup>3</sup> Decision support systems include computer‐based information systems aimed at support of decision‐making.<br/><sup>4</sup> Administrative improvements include audit, documentation, computers. </p> <p>N/A: not applicable</p> </div> </div> </section> <section id="CD004371-sec-0058"> <h4 class="title">1. Drug regimen simplification vs usual care</h4> <p>Seven studies attempted to simplify the drug regimen (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>). Two studies (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>) used a regimen with reduction of daily dosing, whereas the other five studies used a fixed‐dose combination or 'polypill' regimen (<a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>). </p> <p>We were unable to pool data, as the study publications provided insufficient data, so we describe the results for each of the individual studies below. </p> <p><b>Medication adherence ‐</b> Reducing medication intake from four times to twice daily improved mean medication intake by 11% (96% in the intervention group vs 85% in the control group; P = 0.01; n = 29) (<a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>). Drug modification, by administering colestyramine bars instead of powder to make intake easier, did not decrease the adherence rate (91.8% in the intervention group vs 94.8% in the control group; P &gt; 0.05; n = 83) (<a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>). </p> <p>In the five studies that used a fixed‐dose combination (FDC) or polypill, four out of five studies showed better adherence with the polypill compared with the separate dosing regimens. </p> <p>In <a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>, the polypill group showed improved adherence compared with the group receiving separate medications after nine months of follow‐up: 50.8% vs 41%; P = 0.019 (for the intention‐to‐treat population) and 65.7% vs 55.7%; P = 0.012 (for the per‐protocol population); n = 458 (per‐protocol population). </p> <p>In <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a> participants in the polypill‐based strategy showed greater use of treatment compared to those receiving separate medications after a median of 18 months (70% vs 47%; risk ratio (RR) 1.49, 95% confidence interval (CI) 1.30 to 1.72; P &lt; 0.0001; number needed to treat for an additional beneficial outcome (NNTB) 4 (95% CI 3 to 7); n = 623). </p> <p>In the <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a> study, discontinuation rates were 23% in the polypill group vs 18% in the placebo group (RR 1.33, 95% CI 0.89 to 2.00; P = 0.2; n = 373). </p> <p>In <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a> (n = 513) adherence was greater with the FDC than with usual care at 12 months (81% vs 46%; RR 1.75, 95% CI 1.52 to 2.03; P &lt; 0.001; NNTB 3, 95% CI 2 to 4). Adherence specifically for the statins was not different in the FDC group (94% vs 89%; P = 0.06). </p> <p>In <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a> using FDC improved adherence vs usual care (86% vs 65%; RR 1.33, 95% CI 1.26 to 1.41; P &lt; 0.001; n = 1921). </p> <p><b>Total serum cholesterol ‐</b><a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a> demonstrated low‐/high‐density lipoprotein (LDL/HDL) change from means of 215/46 mg/dl at baseline, to 94/59 mg/dl after run‐in, to 85/52 mg/dl after eight months of controlled‐release niacin, and to 98/56 mg/dl after eight months of regular niacin (regular niacin vs controlled‐release niacin, P &lt; 0.005/ &lt; 0.05). The target of LDL &lt; 100 mg/dl was achieved at eight months by 83% of these participants with controlled‐release niacin and by 52% with regular niacin (P &lt; 0.01). </p> <p>In <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>, total cholesterol decreased by 16% in the bar group and 17% in the powder group (P &lt; 0.01). LDL‐cholesterol decreased by 28% and 29% in the bar and powder groups respectively (P &lt; 0.01). There was no change in HDL cholesterol. Triglycerides increased in both groups, by 29% in the bar group and by 25% in the powder group. There was no difference between bar and powder in the effect on blood lipids. </p> <p>In the five studies that used a FDC or polypill, two out of five studies found a reduction in LDL‐cholesterol levels with the polypill as compared with the separate dosing regimens (<a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>). </p> <p><a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a> did not find a difference in mean low‐density lipoprotein cholesterol levels (89.9 mg/dl vs 91.7 mg/dl) between the groups receiving the polypill or the three drugs administered separately. </p> <p>In <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a> there was no difference in total cholesterol levels in the polypill‐based strategy compared to those receiving separate medications after a median of 18 months (0.08 mmol/l, 95% CI 0.06 to 0.22; P = 0.26). </p> <p>The <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a> study found a reduction in LDL‐cholesterol of 0.8 mmol/L, 95% CI 0.6 to 0.9 in favour of the group that was given the polypill. </p> <p><a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a> did not find any difference in LDL‐cholesterol levels between the FDC group and the control group (difference −0.05 mmol/L (−0.20 vs −0.15, 95% CI −0.17 to 0.08; P = 0.46)). </p> <p><a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a> found a difference in LDL‐cholesterol in favour of the FDC group (difference −4.2 mg/dL, 95% CI −6.6 to −1.9 mg/dL; P &lt; 0.001) at the end of the study. </p> <p><b>Blood pressure ‐</b> In the studies that used a FDC or polypill, three out of five studies found a reduction in systolic blood pressure (SBP) with the intervention groups as compared with the separate dosing regimens (<a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; <a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a>). <a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a> and <a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a> do not report effects on blood pressure. </p> <p><a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a> did not find a difference in mean SBP (129.6 mmHg vs 128.6 mm Hg) between the groups receiving the polypill or the three drugs administered separately. </p> <p>In <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a> there was no difference in SBP in the polypill‐based strategy compared to those receiving separate medications after a median of 18 months (1.5 mmHg, 95% CI 4.0 to 1.0; P = 0.24). </p> <p>The <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a> study found a reduction in SBP of 9.9 mmHg, 95% CI 7.7 to 12.1 in favour of the group that was given the polypill. </p> <p><a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a> showed reductions in SBP (−2.6 mmHg, 95% CI −4.0 to −1.1 mmHg; P &lt; 0.001) in the FDC group vs the usual care group. </p> <p><a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a> showed reduction of SBP (−2.6 mmHg, 95% CI −4.0 to −1.1 mmHg) in the FDC group compared with the usual care group at the end of the study. </p> <p><b>Adverse events ‐</b> </p> <p><a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a> did not find a difference in number of adverse events between the groups receiving the polypill or the three drugs administered separately (35.4% vs 32.5%, respectively).There were 21 reported serious adverse events (6.0%) in the polypill group vs 23 (6.6% in the control group). There was 1 death in each group (0.3% vs 0.3%). </p> <p>In <a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a> there was at least one serious adverse event reported in 46.3% of participants in the polypill group vs 40.7% in the usual care group (P = 0.16). </p> <p>The <a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a> study 58% in the polypill group reported adverse events compared with 42% in the control group (P = 0.001) The authors report that the side effects were known side effects of the medication contained in the polypill. Four serious adverse events were reported in each group (polypill group: chest pain, newly diagnosed Type 2 diabetes, removal of wisdom teeth, syncope; placebo group: syncope,<br/>depression, transient ischaemic attack, hip fracture). No deaths, major vascular events, major bleeds or episodes of gastrointestinal ulceration were reported. </p> <p>In <a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a> the number of participants with serious adverse events was not different between groups (fixed dose combination 99 vs usual care 93, P = 0.56). Four deaths occurred in the group with fixed dose combination and 6 in the usual care group (P = 0.75). </p> <p><a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a> showed no significant differences in serious adverse events (5% in the foxed dose combination group and 3.5% in the usual care group (P = 0.09) between the groups. Seventeen deaths occurred in the fixed dose combination group vs 15 in the usual care group (P = 0.72). </p> </section> <section id="CD004371-sec-0059"> <h4 class="title">2. Patient education and information vs usual care</h4> <p>Five studies including 8116 participants intended to improve medication adherence by improving patient information and eduction. No consistent improvement was found (<a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>; <a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>; <a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; <a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; <a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>). </p> <p><b>Medication adherence ‐</b> Pharmacist‐mediated information and postal backups, where videotapes, booklets and newspapers were handed out by the local pharmacist followed by educational newsletters sent by post, successfully improved adherence in people who had started taking statins within 60 days before recruitment into the study, but did not improve adherence in those who had been taking statins for more than 60 days before recruitment into the study (<a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>). In participants who had started taking statins within 60 days before recruitment into the study, the increase in adherence was 13% (92% in intervention group vs 79% in control group; P ≤ 0.005). In participants who had been taking statins for more than 60 days before recruitment into the study, adherence to long‐term therapy was not improved (92% vs 91%; P value reported as non‐significant but not based on a correct interaction test). </p> <p>Another study applied a less personal approach, by sending out videotapes to members of a health maintenance organisation who were known to have a pharmacy claim for statins (<a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>), not increasing adherence rates (73% in intervention group vs 70% in control group; P &gt; 0.05; n = 568). </p> <p>Medication Event Monitoring Systems (MEMS) revealed that those who received text messages for antiplatelets had a higher percentage of correct doses taken (t(36) = 2.5; P = 0.02), percentage number of doses taken (t(31) = 2.8; P = 0.01), and percentage of prescribed doses taken on schedule (t(37) = 2.6; P = 0.01; n = 84). Text message response rates were higher for antiplatelets (M = 90.2%; SD = 9) than statins (M = 83.4%; SD = 15.8) (t(26) = 3.1; P = 0.005). Self‐reported adherence revealed no differences among groups (<a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>). </p> <p>In another study, participants received a starter pack containing a videotape, an educational leaflet, details of the free‐phone patient helpline and website, and labels with a reminder to take study medication. Participants also received regular personalised letters and phone calls throughout the study. The compliance‐enhancing programme was only effective in statin‐naïve participants at three and six months, but had no overall effect over 12 months (80% vs 76% and 78% vs 73%; P &lt; 0.01; n = 6872) (<a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a>). </p> <p>In <a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a> participants in the intervention group received education from the pharmacists tailored to identified misconceptions and beliefs about their medication. However, at the end of the study (after 12 months) there was no difference in adherence: 29% of the participants in the intervention group were non‐adherent compared with 25% in the control group (P = 0.605; n = 137). </p> <p><b>Total serum cholesterol ‐</b><a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a> reports that at month 12, 2231 (68.2%) of participants on rosuvastatin plus compliance initiatives and rosuvastatin alone ‐ 2152 (68.4%) were reported as achieving LDL‐cholesterol &lt; 115 mg/dl (P = 0.97), and 1894 (57.6%) of participants on rosuvastatin plus compliance initiatives and 1837 (57.9%) on rosuvastatin alone reported achieving total cholesterol &lt; 190 mg/dl; P = 0.8732; n = 6872. </p> </section> <section id="CD004371-sec-0060"> <h4 class="title">3. Intensified patient care vs usual care</h4> <p>Sixteen studies randomising 22,785 participants and reporting outcomes on 13,602 participants, investigated the effect of intensified patient care. Reinforcing people to take their medication in the form of written postal material, telephone or other reminders was associated with improved adherence in 10 studies, with results from eight trials reaching statistical significance. There was a positive trend towards improvement in lipid levels in two studies (<a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>). </p> <p>Pooling of data for medication adherence at up to six months included <a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; <a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>; <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>. Pooling of data for medication adherence at more than six months included <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>;<a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>. </p> <p>Of the 16 RCTs with an intensified patient care intervention, five studies used continuous instead of dichotomous outcomes or cumulative results, and could not be included in the pooled data for medication adherence (<a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a>; <a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>; <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>; <a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>). For <a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>, low recruitment and high drop‐out rate had a significant impact on the study power (reducing it to 44%) to detect changes in adherence levels but study had sufficient power to detect a statistically and clinically significant difference in total cholesterol levels. </p> <p>We could not include <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a> in the pooled data for medication adherence, as this study was very different from the other studies; the medications used, niacin and bile acid salts, had very low adherence due to side effects. In <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>, for medication adherence at more than six months, outcome adherence with colestipol was much lower than with lovastatin, due to side effects, so we used lovastatin adherence for pooling of data. <a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a> could not be included in the pooled data as outcome measures included combined data from blood pressure and lipid‐lowering medications. </p> <p><b>Medication adherence</b> </p> <p>Sixteen studies report medication adherence for intensified vs usual care interventions (see <a href="#CD004371-tbl-0003">Table 2</a>); seven provided data for pooling of short‐term adherence and three studies for long‐term adherence. We describe the pooled results below, and report results for the studies that could not be pooled here. </p> <div class="table" id="CD004371-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Intensified vs usual care: Medication adherence outcomes for pooled studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Effective Y/N</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Results</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. "><b>Faulkner 2000</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regular phone calls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24% absolute difference (63% in intervention group vs 39% in control group; P &lt; 0.05 reported; n = 30) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. "><b>Márquez 2004</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regular phone calls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29% absolute difference (93% in intervention group vs 64% in control group; P &lt; 0.001 reported; n = 115) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. "><b>Vrijens 2006</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regular review by the community pharmacist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5% difference (95.9% in the intervention group vs 89.4% in the control group; P &lt; 0.001 reported; n = 392) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]"><b>Derose 2012</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Automated telephone calls followed 1 week later by letters for continued nonadherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statins were dispensed to 42.3% of intervention participants and 26.0% of control participants (absolute difference 16.3%; P = 0001; n = 5216) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. "><b>Márquez 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simple calendar reminder of medication taking given to patient at time of their first prescription </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32% difference (90% in intervention group vs 58% in control group; P &lt; 0.005 reported; n = 186) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. "><b>Guthrie 2001</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone and postal reminders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.7% in intervention group vs 77.4% in control group; P value non‐significant; n = 4548 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. "><b>Schectman 1994</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone and postal reminders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88% in intervention group vs 82% in control group; P = 0.32; n = 162</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. "><b>Aslani 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individualised adherence support service delivered at baseline and 3, 6, 9 months to address issues identified from a questionnaire. Interventions included counselling and advice about the disease, medicine, medicine use, adherence and lifestyle measures. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Main effect F<sub>2,178</sub> = 4.3; P &lt; 0.05; contrast F<sub>1,89</sub> = 5.7; P &lt; 0.05; the intervention group reported that, compared with the control group, they were more liable to alter the dose of their medicine at the third reading compared to the second reading (F<sub>1,89</sub> = 4.97; P &lt; 0.05) (n = 142) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. "><b>Eussen 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community pharmacy–based pharmaceutical care programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower rate of discontinuation within 6 months after initiating therapy versus usual care (HR 0.66; 95% CI 0.46 to 0.96; n = 899); no difference between groups at 12 months (HR 0.84; 95% CI 0.65 to 1.10) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]"><b>Goswami 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Integrated intervention programme (nurse counselling, adherence tip sheet, copay relief card, opportunity to enrol in 12‐week cholesterol management programme) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.66; 95% CI 0.46 to 0.96; No significant difference between groups in discontinuation at 12 months (HR 0.84; 95% CI 0.65 to 1.10) (n = 208) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. "><b>Kardas 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Educational counselling at each visit (every 8 weeks) and asked to adopt a routine evening activity of choice for a reminder </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ± SD MPR was 95.4 ± 53.7% and 81.7 ± 31.0%, for intervention and control group, respectively (P &lt; 0.05; n = 196) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]"><b>Ma 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacist‐delivered telephone counselling calls post‐hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The continuous multiple interval (CMA) for statin medication use was 0.88 (SD = 0.3) in the PI condition (referring to the participant being 88% adherent to their statins medication), and 0.90 (SD = 0.3) in the usual care condition (P = 0.51) (n = 559) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. "><b>Nieuwkerk 2012</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nurse‐led cardiovascular risk‐factor counselling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin adherence was significantly higher (P &lt; 0.01) and anxiety was significantly lower (P &lt; 0.01) in the intervention group (n = 181) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. "><b>Ho 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacist‐led counselling, patient education, teamwork with participant's primary physician, and voice messaging </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.3% in the intervention group were adherent vs 73.9% in the usual care group (P = 0.003) (n = 241) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]"><b>Fang 2015</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short message service (SMS) and SMS plus Micro Letter (ML)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMS and SMS + ML groups had better cumulative adherence after 6 months than the phone group. The SMS + ML group had better cumulative adherence than the SMS group (n = 271) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. "><b>Wald 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Texts sent daily for 2 weeks, alternate days for 2 weeks and weekly thereafter for 22 weeks using an automated computer programme </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>improvement in adherence affecting 16 per 100 participants (95% CI 7 to 24), P = 0.001 (n = 301) </p> </td> </tr> </tbody> </table> </div> <p>In <a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a> (n = 97), Medication Adherence Report Scales showed no changes in medicine adherence scores, although intervention participants were less likely to take less than the prescribed dose after the first‐time interval (main effect F<sub>2,178</sub> = 4.3; P &lt; 0.05; contrast F<sub>1,89</sub> = 5.7; P &lt; 0.05), and the intervention group reported that compared with the control group they were more liable to alter the dose of their medicine at the third reading compared to the second reading (F<sub>1,89</sub> = 4.97; P &lt; 0.05). </p> <p>In <a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>, the intervention group received educational counselling at each visit (i.e. every eight weeks) and were also asked to adopt a routine evening activity of their choice for a reminder. Study arms differed in their level of adherence: mean ± SD MPR was 95.4% ± 53.7% and 81.7% ± 31.0%, for intervention and control groups respectively (P &lt; 0.05; n = 196). </p> <p>Participants in the intervention group of <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a> (n = 559) received five pharmacist‐delivered telephone counselling calls post‐hospital discharge. The continuous multiple interval (CMI) for statin medication use was 0.88 (SD 0.3) in the pharmacy‐delivered intervention (PI) (referring to the participant being 88% adherent to their statins medication), and 0.90 (SD 0.3) in the usual care condition (P = 0.51), leading to the conclusion that a pharmacist‐delivered intervention aimed only at improving participant adherence is unlikely to positively affect outcomes. </p> <p><a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a> (n = 181) demonstrated that statin adherence was higher (P &lt; 0.01) and anxiety was lower (P &lt; 0.01) in the intervention group, which received nurse‐led cardiovascular risk‐factor counselling than in the routine‐care group. </p> <p>In <a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a> (n = 271) participants who were randomised to the short message service (SMS) and those in the SMS + Micro Letter group had better cumulative adherence (lower Morisky Medication Adherence Scale scores) after six months than the phone group. The SMS + Micro Letter group had better cumulative adherence (lower Morisky Medication Adherence Scale scores) than the SMS‐alone group. </p> <section id="CD004371-sec-0061"> <h5 class="title">Pooling of the results</h5> <p>We grouped the results into long‐term adherence and short‐term outcomes. We defined short‐term results as those outcomes measured at up to six months, and long‐term outcomes as measured at more than six months. We then pooled results according to long‐term or short‐term outcomes. When it was not provided, we estimated the SD for the difference between means using the formula σ<sub>d</sub> = sqrt ( σ<sub>1</sub><sup>2</sup> / n<sub>1</sub> + σ<sub>2</sub><sup>2</sup> / n<sub>2</sub> ). We estimated the SDs for <a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a> and <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>. </p> <p>The forest plots in <a href="./references#CD004371-fig-0004" title="">Analysis 1.1</a> and <a href="./references#CD004371-fig-0005" title="">Analysis 1.2</a> both show pooled treatment effects of the intensification of patient care category of interventions when compared with usual care and using adherence measures as an outcome in both short‐term and long‐term measures. Forest plots in <a href="./references#CD004371-fig-0007" title="">Analysis 1.4</a> show the pooled effect estimate for total cholesterol level over both short‐ and long‐term follow‐up. </p> <p>We did not adjust the <a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a> data for clustering as the expected clustering effect of patients within pharmacies in Australia is very low (<a href="./references#CD004371-bbs2-0106" title="ArmourC , Bosnic-AnticevichS , BrilliantM , BurtonD , EmmertonL , KrassI , et al. Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community. Thorax2007;62:496-592.">Armour 2007</a>). </p> <section id="CD004371-sec-0062"> <h6 class="title">Medication adherence at ≤ 6 months</h6> <p>Pooling of data for medication adherence at up to six months using per‐protocol analysis of dichotomous outcomes included seven studies involving 11,204 participants. There was considerable heterogeneity (I² = 88%). Meta‐analysis using a random‐effects model estimated an odds ratio of 1.93 (95% CI 1.29 to 2.88; 7 studies; 11,204 participants; moderate‐quality evidence), favouring the intervention (<a href="./references#CD004371-fig-0004" title="">Analysis 1.1</a>). Removing the three studies with less intensive interventions that contributed to the heterogeneity (as is also apparent from the forest plot) from the pooled analysis (<a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>) resulted in an of OR 1.19 (95% CI 1.02 to 1.39; I² = 0%), favouring the intervention. All but one study (<a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>) had low attrition rates. A sensitivity analysis excluding <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>, which had very high attrition (only 35% of surveys were returned to the investigators), resulted in an OR 2.22, 95% CI 1.41 to 3.49 (<a href="./references#CD004371-fig-0010" title="">Analysis 1.7</a>). The conclusions remained unaltered (<a href="./full#CD004371-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD004371-sec-0063"> <h6 class="title">Medication adherence at &gt; 6 months</h6> <p>Pooling of data for medication adherence at more than six months using per‐protocol analysis of dichotomous outcomes included three studies involving 663 participants. The studies were homogeneous (I² = 0%). Meta‐analysis using a random‐effects model estimated an odds ratio of 2.87 (95% CI 1.91 to 4.29; 3 studies; 663 participants; high‐quality evidence), favouring the intervention (<a href="./references#CD004371-fig-0005" title="">Analysis 1.2</a>). Using a fixed‐effect model did not alter the estimate (OR = 2.87, 95% CI 1.92 to 4.30) nor the conclusions. </p> <p>Although <a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a> contributes 59% of the weighting, the estimate remains robust if this study is removed: the result is OR 3.82, 95% CI 2.03 to 7.18; I² = 0%, favouring the intervention, and hence the overall conclusion remained unchanged (<a href="./full#CD004371-tbl-0001">summary of findings Table 1</a>). </p> <p><b>Total serum cholesterol and low‐density lipoprotein cholesterol ‐</b> From the 16 RCTs that used intensified patient care, five studies (<a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; <a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; <a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a>; <a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>; <a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>) did not use lipid levels as an outcome measure. </p> <p><a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a> reported adjusted levels of total cholesterol at three months, but did not report the raw data for inclusion in the meta‐analysis. <a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a> also reported a decrease in total cholesterol, LDL, and triglycerides with constant HDL, but it did not include any raw data except for baseline measures. <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a> did not provide baseline or change scores and cholesterol data included participants not receiving lipid‐lowering medications. However, no other studies reported the same time point for comparison. <a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a> was not included, as the lipid level data were compiled as an average of three time points: three months, nine months, and 18 months. <a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a> could not be included in the pooled data as cholesterol data included participants not taking lipid‐lowering medications. Means and SD were pooled and compared for <a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a> at up to six‐month time points. Additionally, the means and SD were compared for <a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a> and <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a> at more than six months. </p> <p>The studies that we could not pool are described here.</p> <p><a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a> reported a significant decline in mean total cholesterol and LDL‐cholesterol levels in those receiving pharmaceutical care. Total cholesterol and LDL‐cholesterol decreased by a mean of 17.2 mg/dL, 95% CI 12.3 to 22.0, and 9.47 mg/dL, 95% CI 5.02 to 13.9 respectively. Three months after initiating statin therapy 65% of participants achieved a target LDL‐cholesterol level of ≤ 115 mg/dL. The intervention appeared to have a sustained effect, given the fact that at six and 12 months after treatment, these percentages were 72% and 77% respectively. </p> <p><a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a> reported that both the control and intervention groups had decreases in total cholesterol, LDL‐cholesterol, and triglycerides, with a relatively constant level of HDL‐cholesterol. At the end of the 48‐week follow‐up period, the two groups showed no differences in these lipid parameters. </p> <p>In a study of 689 individuals, <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a> found no differences in those receiving the pharmacist‐delivered intervention versus usual care. Sixty‐five per cent of individuals achieved a goal LDL‐cholesterol of &lt; 100 mg/dl in the intervention group versus 65% (P = 0<i>.</i>29). After 12 months there were no differences in total cholesterol, LDL‐cholesterol, HDL‐cholesterol, or triglycerides between the two groups. </p> <p><a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a> found that the LDL‐cholesterol was lower in the intensified patient care group when compared to the routine‐care group during follow‐up in primary prevention participants, but not in secondary prevention participants. </p> <p><a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a> found no differences in serum cholesterol (4.20 mmol/L versus 4.21 mmol/L total cholesterol and 2.29 mmol/L versus 2.22 mmol/L LDL‐cholesterol) between the Text and No‐text groups respectively. </p> </section> </section> <section id="CD004371-sec-0064"> <h5 class="title">Pooling of the results</h5> <p><b>Reduction in total serum cholesterol (mg/dL) at ≤ 6 months:</b> </p> <p>Pooling of data for total serum cholesterol at up to six months using per‐protocol analysis of continuous outcomes included four studies with 430 participants. There was considerable heterogeneity (I² = 89%). Meta‐analysis using a random‐effects model produced a mean difference (MD) of 17.15, 95% CI 1.17 to 33.14; 4 studies; 430 participants; low‐quality evidence, favouring the intervention (<a href="./references#CD004371-fig-0006" title="">Analysis 1.3</a>). Removing the studies that contributed most to the heterogeneity from the pooled analysis resulted in MD 3.79, 95% CI ‐2.42 to 10.00; I² = 18%, favouring the intervention but not reaching statistical significance. The smaller reductions in the <a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a> study may have been related to the fact that participants were being treated for hyperlipidaemia at the time and were already on therapy, whereas in <a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; <a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>, participants were relatively statin‐naïve and either had therapy initiated or intensified, which would account for a greater initial decline in lipid levels. We used mean difference here as it has a more direct clinical meaning and is easier to interpret compared to the standardised mean difference (SMD). Also, using SMD did not change the conclusion of the analysis (<a href="./full#CD004371-tbl-0001">summary of findings Table 1</a>) </p> <p><b>Reduction in total serum cholesterol (mg/dL) at &gt; 6 months:</b> </p> <p>Pooling of data for total serum cholesterol at up to six months using per‐protocol analysis of continuous outcomes included two studies with 127 participants. The studies were homogeneous (I² = 0%). Meta‐analysis using a random‐effects model produced an MD of 17.57, 95% CI 14.95 to 20.19; 2 studies; 127 participants; high‐quality evidence, favouring the intervention (<a href="./references#CD004371-fig-0007" title="">Analysis 1.4</a>). Using a fixed‐effect model did not change the overall estimate (<a href="./full#CD004371-tbl-0001">summary of findings Table 1</a>). </p> <p><b>Reduction in LDL‐cholesterol (mg/dL) at ≤ 6 months:</b> </p> <p>Pooling of data for low‐density lipoprotein cholesterol at up to six months using per‐protocol analysis of continuous outcomes included three studies with 333 participants. There was moderate heterogeneity (I² = 53%). Meta‐analysis using a random‐effects model produced a MD of 19.51, 95% CI 8.51 to 30.51; 3 studies; 333 participants; moderate‐quality evidence, favouring the intervention (<a href="./references#CD004371-fig-0008" title="">Analysis 1.5</a>). Removing the studies that contributed to the heterogeneity from the pooled analysis resulted in MD 9.00, 95% CI ‐3.57 to 21.57, favouring the intervention, but not reaching statistical significance (<a href="./full#CD004371-tbl-0001">summary of findings Table 1</a>). </p> <p><b>Reduction in LDL‐cholesterol (mg/dL) at &gt; 6 months:</b> </p> <p>Pooling of data for LDL‐cholesterol at more than six months using per‐protocol analysis of continuous outcomes included one study with 30 participants. Meta‐analysis using a random‐effects model estimated a MD of 18.00, 95% CI 5.12 to 30.88, favouring the intervention (<a href="./references#CD004371-fig-0009" title="">Analysis 1.6</a>) (<a href="./full#CD004371-tbl-0001">summary of findings Table 1</a>). </p> </section> </section> <section id="CD004371-sec-0065"> <h4 class="title">4. Complex behavioural approaches vs usual care</h4> <p><b>Medication adherence ‐</b> Only one trial (<a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a>) used a group behavioural approach, where participants initially attended small‐group training followed by postal information. The adherence in the intervention group was no different from the control group (88.5% in intervention group versus 83.8% in control group, P &gt; 0.05; n = 108). </p> <p><b>Total serum cholesterol ‐</b> There were differences between intervention and control groups for TC, LDL and HDL. Compared final mean differences in the intervention groups vs the control groups were: 7.5 mg/dl reduction in mean TC (P &gt; 0.05); 5.2 mg/dl reduction in mean LDL (P &gt; 0.05), 2.1 mg/dl increase in mean HDL (P &gt; 0.05), and 30 mg/dl reduction in mean triglyceride levels (TRG) (P &lt; 0.05). </p> </section> <section id="CD004371-sec-0066"> <h4 class="title">5. Decision support systems vs complex behavioural approaches</h4> <p><b>Medication adherence ‐</b> In <a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a> (n = 108) the median PDC360 (25th – 75th percentile) was 90.0% (76.75 – 98.25) in the counselling/ERD group, 91.0% (76.00 – 99.00) in the ERD group and 87.5% (75.00 – 99.00) in the control group (ITT analysis). We found no differences in the median refill adherence. In <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a> (n = 1692) there was no difference between participants in the study arms that received adherence information and motivational interviewing when compared with usual care. </p> <p><b>Total serum cholesterol ‐</b> This outcome was not reported in <a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>. In <a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a> there were no differences in LDL‐cholesterol levels between the different groups (P = 0.084). </p> </section> <section id="CD004371-sec-0067"> <h4 class="title">6. Administrative improvements vs usual care</h4> <p><b>Medication adherence ‐</b> In <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a> (n = 2293) participants in the intervention group were more likely to have their drug profile reviewed compared to those in the control group (44.5% vs 35.5%; OR 1.46; P &lt; 0.001). Overall, however, there was no difference in the magnitude of the decline in adherence between the intervention and control group (mean –6.2 (intervention) vs –6.4 (control); P = 0.90). In <a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a> (n = 5855) rates of full adherence (defined as having a supply of medications available on at least 80% of days during follow‐up) for statins were 41.9% in the usual care group and 49.3% in the full‐coverage group (increase by 6.2 percentage points, 95% CI 3.9 to 8.5); OR 1.36, 95% CI 1.18 to 1.56; P &lt; 0.001. Rates of adherence to other medications for which copayments remained the same were no different between the two study groups. </p> <p><b>Total serum cholesterol ‐</b> This outcome was not reported in <a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a> or <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a>. </p> <p><b>Costs ‐</b><a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a> evaluated costs related to the intervention and found that elimination of co‐payments in the intervention group did not increase total spending for the health system (USD 66,008 for the full‐coverage group and USD 71,778 for the usual‐coverage group; relative spending 0.89, 95% CI 0.50 to 1.56; P = 0.68). Participants in the intervention group paid less for drugs and other services (relative spending 0.74, 95% CI 0.68 to 0.80; P &lt; 0.001). </p> </section> <section id="CD004371-sec-0068"> <h4 class="title">7. Large‐scale pharmacy‐led automated telephone intervention vs usual care</h4> <p><a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a> (n = 861,894) included two interventions on nearly a million participants, initiated by a commercial pharmacy dispensing medications. One intervention consisted of automated phone calls to participants on the third and seventh days after a prescription was processed but remained unpurchased. The other intervention was a live intervention which used calls from a pharmacist or technician to participants who still had not picked up their prescriptions after eight days. Data for analysis were obtained following the interventions being commercially conducted. Data were not recorded on whether pharmacists or technicians left a message or actually spoke with participants, or on the content of conversations. In <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a> the intervention consisted of automated phone reminders using interactive voice recognition to participants when they were due or overdue for a refill. Participants in the enhanced study arm also received a letter if they were 60 to 89 days overdue. This study randomised 16,280 participants. </p> <p><b>Medication adherence ‐</b><a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>: For the automated intervention, the proportion of abandoned prescriptions was 4.2% in the intervention group and 4.5% in the control group (P = 0.23). For antihypertensives, the proportion of abandoned prescriptions was 3.7% in the intervention group and 4.1% in the control group (P = 0.06), whereas for antihyperlipidaemics the proportions were the same (6.0%). </p> <p>For the live intervention, the proportion of abandoned prescriptions was 36.9% in the intervention group and 41.7% in the control group, a difference of 4.8% (P &lt; 0.0001). The difference for antihypertensives was 6.9% (P &lt; 0.0001) but for antihyperlipidaemics was only 1.4 (P = 0.25) </p> <p>In <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a> (n = 16,366) statin adherence increased for both intervention groups compared with usual care, but adherence was no different between the phone group and the enhance phone group. On average, adherence among the group that only received the phone calls was 2.2 percentage points higher than for usual care (95% CI 1.1 to 3.4), while the difference was 3.0, 95% CI 1.9 to 4.2 percentage points for the group that also received a reminder letter. </p> <p><b>Total serum cholesterol ‐</b> This outcome was not reported in <a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>. In <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a> a reduction in LDL‐cholesterol levels was found among the participants receiving phone calls and a letter, compared to usual care (mean difference –1.5, 95% CI –2.7 to –0.2 mg/dL; P = 0.019). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004371-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004371-sec-0069"></div> <section id="CD004371-sec-0070"> <h3 class="title" id="CD004371-sec-0070">Summary of main results</h3> <p>This updated systematic review identified new evidence to suggest that patient interventions which we grouped as intensified patient care may improve patient adherence to lipid‐lowering therapy when compared to usual care. These types of interventions took the form of telephone reminders, calendar reminders, integrated multidisciplinary educational activities and pharmacist‐led interventions. The interventions appeared to be effective in improving medication adherence, both over the short term (up to six months) and the long term (more than six months). Physiologic outcome data in the form of cholesterol levels also demonstrated significant improvement over short‐term and long‐term periods. The effectiveness of these types of interventions was sustained even when we removed studies contributing to heterogeneity from the analysis. </p> <p>Other types of interventions which we grouped as drug regimen simplification, complex behavioural approaches, decision support systems, administrative improvements, and a large‐scale pharmacy‐led automated telephone intervention did not consistently show an overall improvement in adherence rates or other physiologic measures of adherence. Some outcomes were not measured in all studies and comparisons were made only where possible. </p> </section> <section id="CD004371-sec-0071"> <h3 class="title" id="CD004371-sec-0071">Overall completeness and applicability of evidence</h3> <p>The significant increase in research activity in this field has yielded more robust data from which to draw conclusions. In the studies classified as intensification of patient care, enough high‐quality studies exist with similar outcomes where we noted significant trends favouring the interventions. The types of studies in this category included large groups of outpatients and would seem to be generalisable to other outpatient cohorts. Studies in the other categories could address the objectives of our meta‐analysis, but given the relatively small number of comparable studies with similar interventions and outcome measures, no clear trends emerged. </p> <p>The interventions in the intensified patient care group are of a type which is applicable to current practice. Many large healthcare systems are evaluating methods to improve the health of large populations of patients. Large‐scale structural interventions noted in the intensified patient care group of interventions are generally feasible for these types of systems. </p> </section> <section id="CD004371-sec-0072"> <h3 class="title" id="CD004371-sec-0072">Quality of the evidence</h3> <p>The studies in this review investigate the impact of a wide range of interventions on adherence to lipid‐lowering treatments. The nature of the majority of interventions implies that blinding of participants was not possible (e.g. interventions such as reminder phone calls or education sessions). As this is acceptable in a pragmatic context, we have not downgraded the evidence for lack of blinding. Studies demonstrating a fixed dose combination or ‘polypill’ placebo comparison are feasible, but we could not pool them in our review. </p> <p>We assessed the quality of the pooled evidence using the GRADE classification for five pooled outcomes in the comparison of intensification of patient care vs usual care. We graded the evidence for the outcomes of long‐term adherence (more than six months) and reduction in total cholesterol as being of high quality. We rated the short‐term outcomes (up to six months) of patient adherence and LDL‐cholesterol as being of moderate quality. We downgraded these outcomes by one level because of heterogeneity of the pooled data. We downgraded the short‐term outcome of total serum cholesterol to low quality, due to heterogeneity and a wide confidence interval (imprecision). </p> <p>The review authors independently reviewed data at various checkpoints, ensuring the selection of a series of rigorous studies. The review authors believe that systematic error did not threaten the validity of the results of the studies included in this review (see <a href="#CD004371-sec-0051">Risk of bias in included studies</a>). </p> </section> <section id="CD004371-sec-0073"> <h3 class="title" id="CD004371-sec-0073">Potential biases in the review process</h3> <p>We have searched in several different databases, including trials registers, and we have handsearched reference lists in order to identify eligible studies. It is nevertheless still possible that we have missed relevant material. In addition, two review authors selected studies independently, thus minimising the risk of overlooking any. The updated searches in 2015 and 2016 retrieved a considerable number of new studies for inclusion, indicating that the topic is still being actively researched. In order to maintain the relevance of this review, we will therefore attempt to update our searches regularly. The evidence is quite consistent and robust and it may therefore be unlikely that a missed study could have changed our conclusions. </p> <p>The diverse nature of the studied interventions and absence of a standard classification of interventions to improve medication adherence means that studies can be grouped in different ways. We have grouped the studies from the perspective of the health system/provider, as this has relevance to implementation strategies. </p> <p>In the pooled analysis <a href="./references#CD004371-fig-0006" title="">Analysis 1.3</a> the <a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a> study was a clustered RCT, however we did not adjust for clustering as in Australia pharmacies do not serve specific populations. Patients generally purchase their medication from a number of different pharmacies. A study in a similar setting found a clustering effect of ‐0.006, which justifies using uni‐level analysis. It is possible that we have overestimated the effect of the intervention, however, it is unlikely that this will have influenced the conclusion. </p> </section> <section id="CD004371-sec-0074"> <h3 class="title" id="CD004371-sec-0074">Agreements and disagreements with other studies or reviews</h3> <p>The two previous versions of this review concluded that there were no reliable interventions that have been shown to improve adherence rates to lipid‐lowering medications (<a href="./references#CD004371-bbs2-0148" title="SchedlbauerA , SchroederK , PetersTJ , FaheyT . Interventions for improving adherence to lipid lowering medication. Cochrane Database of Systematic Reviews2004, Issue 4. Art. No: CD004371. [DOI: 10.1002/14651858.CD004371.pub2]">Schedlbauer 2004</a>; <a href="./references#CD004371-bbs2-0149" title="SchedlbauerA , DaviesP , FaheyT . Interventions to improve adherence to lipid lowering medication. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD004371. [DOI: 10.1002/14651858.CD004371.pub3]">Schedlbauer 2010</a>). However, this updated review which includes 24 additional studies indicates that interventions classified as intensification of patient care could improve both short‐term and long‐term adherence rates when compared to usual care. </p> <p>An earlier systematic review (<a href="./references#CD004371-bbs2-0129" title="Muller-NordhornJ , WillichSN . Effectiveness of interventions to increase adherence to statin therapy. Disease Management of Health Outcomes2005;13(2):72-82. [1173-8790/05/0002-0073/$34.95/0]">Muller‐Nordhorn 2005</a>), including 10 RCTs, found that interventions (ranging from postal reminders to coaching, delivered by nurses, pharmacists or physicians) was associated with a significant increase in patient adherence to statin therapy compared with the control group in four of the 10 RCTs. The remaining six RCTs found no significant difference in adherence. The authors conclude that “given the inconsistency of the findings and the limitations of certain study designs, RCTs with a large sample size are needed to further investigate the effectiveness of adherence‐increasing interventions in patients with statin therapy.” The most recent systematic review by <a href="./references#CD004371-bbs2-0134" title="RashJA , CampbellDJ , TonelliM , CampbellTS . A systematic review of interventions to improve adherence to statin medication: what do we know about what works?Preventive Medicine2016;90:155-69. [DOI: 10.1016/j.ypmed.2016.07.006]">Rash 2016</a>, which includes 29 RCTs, pooled data for interventions labelled as ‘simplification of drug regimen’, ‘provision of education’, and ‘multi‐faceted interventions’. They conclude that all these types of interventions had a small positive effect on statin adherence, but that additional methodologically rigorous trials are needed. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004371-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/urn:x-wiley:14651858:media:CD004371:CD004371-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004371-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_t/tCD004371-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004371-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/urn:x-wiley:14651858:media:CD004371:CD004371-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD004371-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_t/tCD004371-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004371-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/urn:x-wiley:14651858:media:CD004371:CD004371-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004371-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_t/tCD004371-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004371-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/urn:x-wiley:14651858:media:CD004371:CD004371-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intensified patient care vs usual care, Outcome 1: Medication adherence at ≤ 6 months" data-id="CD004371-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_t/tCD004371-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Intensified patient care vs usual care, Outcome 1: Medication adherence at ≤ 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/references#CD004371-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004371-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/urn:x-wiley:14651858:media:CD004371:CD004371-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intensified patient care vs usual care, Outcome 2: Medication adherence at &gt; 6 months" data-id="CD004371-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_t/tCD004371-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Intensified patient care vs usual care, Outcome 2: Medication adherence at &gt; 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/references#CD004371-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004371-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/urn:x-wiley:14651858:media:CD004371:CD004371-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intensified patient care vs usual care, Outcome 3: Reduction in total serum cholesterol at ≤ 6 mos (mg/dL)" data-id="CD004371-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_t/tCD004371-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Intensified patient care vs usual care, Outcome 3: Reduction in total serum cholesterol at ≤ 6 mos (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/references#CD004371-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004371-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/urn:x-wiley:14651858:media:CD004371:CD004371-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intensified patient care vs usual care, Outcome 4: Reduction in total serum cholesterol at &gt; 6 mos (mg/dL)" data-id="CD004371-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_t/tCD004371-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Intensified patient care vs usual care, Outcome 4: Reduction in total serum cholesterol at &gt; 6 mos (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/references#CD004371-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004371-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/urn:x-wiley:14651858:media:CD004371:CD004371-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intensified patient care vs usual care, Outcome 5: Reduction in LDL‐C at ≤ 6 months (mg/dL)" data-id="CD004371-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_t/tCD004371-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Intensified patient care vs usual care, Outcome 5: Reduction in LDL‐C at ≤ 6 months (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/references#CD004371-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004371-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/urn:x-wiley:14651858:media:CD004371:CD004371-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intensified patient care vs usual care, Outcome 6: Reduction in LDL‐C &gt; 6 months (mg/dL)" data-id="CD004371-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_t/tCD004371-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Intensified patient care vs usual care, Outcome 6: Reduction in LDL‐C &gt; 6 months (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/references#CD004371-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004371-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/urn:x-wiley:14651858:media:CD004371:CD004371-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intensified patient care vs usual care, Outcome 7: Attrition rate sensitivity analysis (medication adherence at ≤ 6 months)" data-id="CD004371-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_t/tCD004371-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Intensified patient care vs usual care, Outcome 7: Attrition rate sensitivity analysis (medication adherence at ≤ 6 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/references#CD004371-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/media/CDSR/CD004371/image_n/nCD004371-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004371-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table for the comparison of 'intensified patient care' vs 'usual care'</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intensified patient care vs usual care</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> People receiving lipid‐lowering medications<br/><b>Setting:</b> Ambulatory <br/><b>Intervention:</b> Intensified patient care<br/><b>Comparison:</b> Usual care </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with usual care</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Intensified patient care</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Medication adherence at ≤ 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.93<br/>(1.29 to 2.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,204<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>456 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>618 per 1,000<br/>(519 to 707) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Medication adherence at &gt; 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.87<br/>(1.91 to 4.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>663<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>705 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>873 per 1,000<br/>(820 to 911) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in LDL‐C at ≤ 6 months (mg/dL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in LDL‐C at ≤ 6 months (mg/dL) was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in LDL‐C at ≤ 6 months (mg/dL) in the intervention group was 19.51 greater (8.51 greater to 30.51 greater) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in total serum cholesterol at ≤ 6 months (mg/dL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in total serum cholesterol at ≤ 6 mos (mg/dL) was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in total serum cholesterol at ≤ 6 months (mg/dL) in the intervention group was 17.15 greater (1.17 greater to 33.14 greater) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>430<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in total serum cholesterol at &gt; 6 mos (mg/dL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in total serum cholesterol at &gt; 6 months (mg/dL) was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in total serum cholesterol at &gt; 6 months (mg/dL) in the intervention group was 17.57 greater (14.95 greater to 20.19 greater) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to heterogeneity<br/><sup>2</sup>Downgraded due to wide confidence interval </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table for the comparison of 'intensified patient care' vs 'usual care'</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004371-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Matrix of comparisons in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><b>Comparator intervention</b> </p> </td> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1) simplification of drug regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>2) patient education and information</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>3) intensified patient care<sup>1</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>4) complex behavioural approaches<sup>2</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>5) decision support systems<sup>3</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>6) administrative improvements<sup>4</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>7) pharmacy‐led intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1) simplification of drug regimen</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>2) patient education and information</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>3) intensified patient care<sup>1</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>4) complex behavioural approaches<sup>2</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0015" title="KooyMJ , Van WijkBL , HeerdinkER , De BoerA , BouvyML . Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology2013;4:69. ">Kooy 2013</a>; </p> <p><a href="./references#CD004371-bbs2-0024" title="PladevallM , DivineG , WellsKE , ResnicowK , WilliamsLK . A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educator2015;41(1):136-46. ">Pladevall 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>5) decision support systems<sup>3</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>6) administrative improvements<sup>4</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>7) pharmacy‐led intervention</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>N/A</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>8) usual care/placebo</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0002" title="BrownBG , BardsleyJ , PoulinD , HillgerLA , DowdyA , MaherVM , et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. American Journal of Cardiology1997;80(2):111-15. ">Brown 1997</a>; </p> <p><a href="./references#CD004371-bbs2-0003" title="CastellanoJM , GinesS , PenalvoJL , BansilalS , Fernandez-OrtizA , AlvarezL , et al. A polypill strategy to improve adherence: results from the FOCUS Project. Journal of the American College of Cardiology2014;64(20):2071-82. [DOI: 10.1016/j.jacc.2014.08.021]">Castellano 2014</a>; </p> <p><a href="./references#CD004371-bbs2-0022" title="PatelA , CassA , PeirisD , UsherwoodT , BrownA , JanS , et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology2015;22(7):920-30. ">Patel 2015</a>; </p> <p><a href="./references#CD004371-bbs2-0023" title="PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLOS One2011;6(5):e19857. ">PILL 2011</a>; </p> <p><a href="./references#CD004371-bbs2-0028" title="SelakV , ElleyCR , BullenC , CrengleS , WadhamA , RafterN , et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ2014;348:g3318. ">Selak 2014</a>; </p> <p><a href="./references#CD004371-bbs2-0029" title="SweeneyME , FletcherBJ , RiceCR , BerraKA , RuddCM , FletcherGF , et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. American Journal of Medicine1991;90(4):469-73. ">Sweeney 1991</a>; </p> <p><a href="./references#CD004371-bbs2-0031" title="ThomS , PoulterN , FieldJ , PatelA , PrabhakaranD , StantonA , et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD (UMPIRE). JAMA2013;310(9):918-29. ">Thom 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0011" title="GujralG , WinckelK , NissenLM , CottrellWN . Impact of community pharmacist intervention discussing patients’ beliefs to improve medication adherence. International Journal of Clinical Pharmacy2014;36(5):1048-58. ">Gujral 2014</a>; </p> <p><a href="./references#CD004371-bbs2-0021" title="ParkLG , Howie-EsquivelJ , ChungML , DracupK . A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Education and Counseling2013;94(2):261-8. ">Park 2013</a>; </p> <p><a href="./references#CD004371-bbs2-0025" title="PostonJ , LohE , DunhamW . The medication use study. Canadian Pharmaceutical Journal1998;131(10):31-8. ">Poston 1998</a>; </p> <p><a href="./references#CD004371-bbs2-0026" title="PowellKM , EdgrenB . Failure of educational videotapes to improve medication compliance in a health maintenance organization. American Journal of Health-System Pharmacy1995;52(20):2196-9. ">Powell 1995</a>; </p> <p><a href="./references#CD004371-bbs2-0035" title="WillichSN , EnglertH , SonntagF , VollerH , Meyer-SabellekW , WegscheiderK , et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention and Rehabilitation2009;16(2):180-7. ">Willich 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. ">Aslani 2010</a>; <a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]">Derose 2012</a>; </p> <p><a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. ">Eussen 2010</a>; <a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]">Fang 2015</a>; <a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. ">Faulkner 2000</a>; </p> <p><a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]">Goswami 2013</a>; </p> <p><a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. ">Guthrie 2001</a><a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. ">Ho 2014</a>; </p> <p><a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. ">Kardas 2013</a>; <a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]">Ma 2010</a>; </p> <p><a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. ">Márquez 2004</a>; </p> <p><a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. ">Márquez 2007</a>; </p> <p><a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. ">Nieuwkerk 2012</a>; </p> <p><a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. ">Schectman 1994</a>; </p> <p><a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. ">Vrijens 2006</a>; </p> <p><a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. ">Wald 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0017" title="Márquez ContrerasE , Casado MartínezJJ , López de AndrésM , Corés PrietoE , López ZamoranoJM , Moreno GarcíaJP , et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion Primaria1998;22(2):79-84. ">Márquez 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0004" title="ChoudhryNK , AvornJ , GlynnRJ , AntmanEM , SchneeweissS , ToscanoM , et al. Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine2011;365(22):2088-97. ">Choudhry 2011</a>; <a href="./references#CD004371-bbs2-0030" title="TamblynR , ReidelK , HuangA , TaylorL , WinsladeN , BartlettG , et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Medical Decision Making2009;30(2):176-88. ">Tamblyn 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004371-bbs2-0009" title="FischerMA , ChoudhryNK , BykovK , BrillG , BoppG , WurstAM , et al. Pharmacy-based interventions to reduce primary medication nonadherence to cardiovascular medications. Medical Care2014;52(12):1050-4. ">Fischer 2014</a>; <a href="./references#CD004371-bbs2-0032" title="VollmerWM , Owen-SmithAA , TomJO , LawsR , DitmerDG , SmithDH , et al. Improving adherence to cardiovascular disease medications with information technology. American Journal of Managed Care2014;20(11 Spec No. 17):SP502-10. ">Vollmer 2014</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>1</sup> Intensified patient care includes increased follow‐up, sending out reminders, etc.<br/><sup>2</sup> Complex behavioural approaches include increasing motivation by arranging group sessions, giving out rewards, etc.<br/><sup>3</sup> Decision support systems include computer‐based information systems aimed at support of decision‐making.<br/><sup>4</sup> Administrative improvements include audit, documentation, computers. </p> <p>N/A: not applicable</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Matrix of comparisons in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004371-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Intensified vs usual care: Medication adherence outcomes for pooled studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Effective Y/N</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Results</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0008" title="FaulknerMA , WadibiaEC , LucasBD , HillemanDE . Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20(4):410-6. "><b>Faulkner 2000</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regular phone calls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24% absolute difference (63% in intervention group vs 39% in control group; P &lt; 0.05 reported; n = 30) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0018" title="Márquez ContrerasE , Casado MartínezJJ , Corchado AlbalatY , Chaves GonzalezR , GrandioA , Losada VelascoC , et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Atencion Primaria2004;33(8):15. "><b>Márquez 2004</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regular phone calls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29% absolute difference (93% in intervention group vs 64% in control group; P &lt; 0.001 reported; n = 115) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0033" title="VrijensB , BelmansA , MatthysK , De KlerkeE , LesaffreE . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety2006;15(2):115-21. "><b>Vrijens 2006</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regular review by the community pharmacist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5% difference (95.9% in the intervention group vs 89.4% in the control group; P &lt; 0.001 reported; n = 392) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0005" title="DeroseSF , GreenK , MarrettE , TunceliK , CheethamTC , ChiuVY , et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Internal Medicine2013;173(1):38-43. [DOI: 10.1001/2013.jamainternmed.717]"><b>Derose 2012</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Automated telephone calls followed 1 week later by letters for continued nonadherence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statins were dispensed to 42.3% of intervention participants and 26.0% of control participants (absolute difference 16.3%; P = 0001; n = 5216) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0019" title="Márquez ContrerasE , Casado MartínezJJ , Motero CarrascoJ , Martín de PablosJL , Chaves GonzalesR , Losada RuizC , et al. Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?Atencion Primaria2007;39(12):661-8. "><b>Márquez 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simple calendar reminder of medication taking given to patient at time of their first prescription </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32% difference (90% in intervention group vs 58% in control group; P &lt; 0.005 reported; n = 186) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0012" title="GuthrieRM . The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clinical Therapeutics2001;23(6):970-80. "><b>Guthrie 2001</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone and postal reminders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.7% in intervention group vs 77.4% in control group; P value non‐significant; n = 4548 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0027" title="SchectmanG , HiattJ , HartzA . Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Annals of Pharmacotherapy1994;28(1):29-35. "><b>Schectman 1994</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telephone and postal reminders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88% in intervention group vs 82% in control group; P = 0.32; n = 162</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0001" title="AslaniP , RoseG , ChenTF , WhiteheadPA , KrassI . A community pharmacist delivered adherence support service for dyslipidaemia. European Journal of Public Health2010;21(5):567-72. "><b>Aslani 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individualised adherence support service delivered at baseline and 3, 6, 9 months to address issues identified from a questionnaire. Interventions included counselling and advice about the disease, medicine, medicine use, adherence and lifestyle measures. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Main effect F<sub>2,178</sub> = 4.3; P &lt; 0.05; contrast F<sub>1,89</sub> = 5.7; P &lt; 0.05; the intervention group reported that, compared with the control group, they were more liable to alter the dose of their medicine at the third reading compared to the second reading (F<sub>1,89</sub> = 4.97; P &lt; 0.05) (n = 142) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0006" title="EussenSR , Van der ElstME , KlungelOH , RompelbergCJ , GarssenJ , OosterveldMH , et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Annals of Pharmacotherapy2010;44(12):1905-13. "><b>Eussen 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Community pharmacy–based pharmaceutical care programme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower rate of discontinuation within 6 months after initiating therapy versus usual care (HR 0.66; 95% CI 0.46 to 0.96; n = 899); no difference between groups at 12 months (HR 0.84; 95% CI 0.65 to 1.10) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0010" title="GoswamiNJ , DekovenM , KuznikA , MardekianJ , KrukasMR , LiuLZ , et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. International Journal of General Medicine2013;6:647-55. [DOI: 10.2147/IJGM.S47518]"><b>Goswami 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Integrated intervention programme (nurse counselling, adherence tip sheet, copay relief card, opportunity to enrol in 12‐week cholesterol management programme) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.66; 95% CI 0.46 to 0.96; No significant difference between groups in discontinuation at 12 months (HR 0.84; 95% CI 0.65 to 1.10) (n = 208) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0014" title="KardasP . An education-behavioural intervention improves adherence to statins. Central European Journal of Medicine2013;8(5):580-5. "><b>Kardas 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Educational counselling at each visit (every 8 weeks) and asked to adopt a routine evening activity of choice for a reminder </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ± SD MPR was 95.4 ± 53.7% and 81.7 ± 31.0%, for intervention and control group, respectively (P &lt; 0.05; n = 196) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0016" title="MaYS , OckeneIS , RosalMC , MerriamPA , OckeneJK , GandhiPJ . Randomized trial of a pharmacist-delivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol2010;2010:383281. [DOI: 10.1155/2010/383281]"><b>Ma 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacist‐delivered telephone counselling calls post‐hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The continuous multiple interval (CMA) for statin medication use was 0.88 (SD = 0.3) in the PI condition (referring to the participant being 88% adherent to their statins medication), and 0.90 (SD = 0.3) in the usual care condition (P = 0.51) (n = 559) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0020" title="NieuwkerkPT , NiermanMC , VissersMN , LocadiaM , Greggers-PeuschP , KnapeLPM , et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. American Journal of Cardiology2012;110(5):666-72. "><b>Nieuwkerk 2012</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nurse‐led cardiovascular risk‐factor counselling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statin adherence was significantly higher (P &lt; 0.01) and anxiety was significantly lower (P &lt; 0.01) in the intervention group (n = 181) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0013" title="HoPM , Lambert-KerznerA , CareyEP , FahdiIE , BrysonCL , MelnykSD , et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Internal Medicine2014;174(2):186-93. "><b>Ho 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacist‐led counselling, patient education, teamwork with participant's primary physician, and voice messaging </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.3% in the intervention group were adherent vs 73.9% in the usual care group (P = 0.003) (n = 241) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004371-bbs2-0007" title="FangR , LiX . Electronic messaging support service programs improve adherence to lipid‐lowering therapy among outpatients with coronary artery disease: an exploratory randomised control study. Journal of Clinical Nursing2015;25(5-6):664-71. [DOI: 10.1111/jocn.12988]"><b>Fang 2015</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short message service (SMS) and SMS plus Micro Letter (ML)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMS and SMS + ML groups had better cumulative adherence after 6 months than the phone group. The SMS + ML group had better cumulative adherence than the SMS group (n = 271) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD004371-bbs2-0034" title="WaldDS , BestwickJP , RaimanL , BrendellR , WaldNJ . Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT Trial). PLoS ONE2014;9(12):e114268. "><b>Wald 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Texts sent daily for 2 weeks, alternate days for 2 weeks and weekly thereafter for 22 weeks using an automated computer programme </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>improvement in adherence affecting 16 per 100 participants (95% CI 7 to 24), P = 0.001 (n = 301) </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Intensified vs usual care: Medication adherence outcomes for pooled studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/full#CD004371-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004371-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intensified patient care vs usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Medication adherence at ≤ 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.29, 2.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Medication adherence at &gt; 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [1.91, 4.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Reduction in total serum cholesterol at ≤ 6 mos (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.15 [1.17, 33.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Reduction in total serum cholesterol at &gt; 6 mos (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.57 [14.95, 20.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Reduction in LDL‐C at ≤ 6 months (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.51 [8.51, 30.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Reduction in LDL‐C &gt; 6 months (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Attrition rate sensitivity analysis (medication adherence at ≤ 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [1.41, 3.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intensified patient care vs usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004371.pub4/references#CD004371-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004371.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004371-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004371-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004371-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD004371-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD004371-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD004371-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD004371-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004371-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004371-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004371\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004371\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004371\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004371\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004371\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004371.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004371.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004371.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004371.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004371.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714061188"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004371.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714061192"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004371.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d65767905937d',t:'MTc0MDcxNDA2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 